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Stellingen bij het proefschrift: 
A, Angiogenesis and Clinical Complications in 
Sickle Cell Disease 
1. De verschillen in serumconcentraties van angiogenese gerelateerde eiwitten 
tussen sikkelcelpatienten en gezonde controles suggereren een rol van 
angiogenese in de pathofysiologie van sikkelcelziekte. ~ dit proefschrift 
2. De hoeveelheid circulerende endotheelcellen lijkt gerelateerd aan de mate van 
orgaanschade bij sikkelcelpatienten maar is niet gerelateerd aan serum- en 
plasma markers van endotheelactivatie. ~ dit proefschrift 
3. Serumconcentraties van SDF-1 zijn in de klinisch asymptomatische fase van 
sikkelcelpatienten hoger dan bij mensen met ernstige ziekte zoals sepsis en zijn 
gerelateerd aan de aanwezigheid van pulmonale hypertensie bij sikkelcelziekte. 
~ dit proefschrift 
4. Om sikkelcelpatienten beter te kunnen behandelen zijn objectieve markers nodig 
om de ontwikkeling van orgaanschade te monitoren. ~ dit proefschrift 
5. Asymmetrische dimethylarginine speelt geen belangrijke rol tijdens de vaso­
occlusieve crise, maar lijkt een rol te spelen in de ontwikkeling van pulmonale 
hypertensie bij sikkelcelziekte. ~ dit proefschrift 
6. Serumspiegels van angiogenese factoren lijken niet gerelateerd te zijn aan de 
aan- of afwezigheid van aan sikkelcelziekte gerelateerde complicaties. ~ dit 
proefschrift 
7. Statistics are like bikinis. What they reveal is suggestive, but what they conceal is 
vital. ~ Aaron Levenstein 
8. It doesn't mean something is useless just because it doesn't do what you planned 
it to do. ~ Thomas Alva Edison 
9. Watch the little things; a small leak will sink a great ship. ~ Benjamin Franklin 
10. Hoe hoger een punt op de politieke agenda, des te meer tijd en middelen hiervoor 
uitgetrokken worden. Afrikaanse of aan Afrika gerelateerde problematiek staat 
Oberhaupt niet op de agenda. 
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INTRODUCTION 
Background 
Sickle cell disease (SCD) is an autosomal recessively inherited hemoglobinopathy 
caused by a single amino acid substitution of valine for glutamic acid (GAG➔GTG) 
in the sixth codon of the �-globin gene leading to the synthesis of sickle hemoglobin 
(HbS).1•2 HbS chains form polymers in the deoxygenated state, leading to the formation 
of characteristic sickle cells. 
The HbSS genotype also known as sickle cell anemia is the most severe form which 
is characterized by the homozygous expression of the defective gene that codes for 
HbS. There are also several heterozygote forms known such as HbSC, HbSD and HbSE 
which are less severe as the homozygote HbSS form. The geographic origin of HbS lies 
in regions of the world where malaria is endemic (i.e., Africa, South Asia, the Middle 
East, and around the Mediterranean) as result of the fact that the heterozygote 
condition (HbAS or sickle cell trait) confers relative resistance to falciparum malaria 
and thus confers a survival advantage.3 As a result of slavery and migration the disease 
is nowadays present throughout the world with an estimated prevalence of sickle cell 
trait ranging from 8% in the Afro-American population of the United States of America 
to 40% in endemic areas in West-Africa, India and Saudi Arabia.4 In Cura!;aO, a small 
island in the Caribbean with 140.000 inhabitants, the prevalence is estimated to be 
5.0% for HbAS with a prevalence of about 0.07% HbSS and 0.18% HbSC patients.5 
SCD is an important hemoglobinopathy characterized by recurrent micro-vascular 
vaso-occlusion, chronic intravascular hemolysis and reduced life expectancy.6•7 
PATHOPHYSIOLOGY 
The mechanisms responsible for the development of SCD-related complications 
are focus of intense research. Many mechanisms contribute to the complex 
pathophysiology of SCD, with dysfunction of the vascular endothelium being 
considered a factor of major importance. A central role in the pathophysiology of SCD 
is attributed to hemolysis and vaso-occlusion. 
Hemolysis 
In SCD hemolysis is driven by HbS polymerization, in such a way that recurrent 
deoxygenation and reoxygenation of erythrocytes result in cell membrane damage. 
Hemolytic anemia varies in intensity among the different genotypes of SCD. It is most 
severe in the homozygote genotype, less severe in double heterozygote genotypes 
and also less severe with co-inheritance of a-thalassemia deletion. Hemolysis 
contributes to the development of vasculopathy which is characterized by pulmonary 
and systemic hypertension, endothelial dysfunction and proliferative changes in the 
inti ma and smooth muscle of blood vessels.8•10 Several complications such as priapism, 
cholelithiasis, leg ulcers and pulmonary hypertension (PHT) have been shown to 
be associated with increased rates of hemolysis resulting in a reduced nitric oxide 
(NO) bioavailability.8•11 The hemolytic rate does not seem to be associated with the 
frequency of vase-occlusive events. Due to the fact that patients with low hemoglobin 
concentrations and high hemolytic rates are more likely to develop vasculopathy than 
are those with higher hemoglobin concentrations, whom also seem more prone to 
episodes of acute painful crisis and possibly acute chest syndrome (ACS), some have 
proposed that SCD patients seem to form distinct subphenotypes driven by hemolysis 
on one and vase-occlusion on the other hand.12•13 
Vaso-occlusion 
Polymerization of erythrocyte hemoglobin has been demonstrated to be responsible 
for the characteristic sickle shape and is thought to play an important role in the 
development of vaso-occlusion. Several decades ago vase-occlusion was understood 
as a transient log-jam of sickle shaped erythrocytes within the small vessels impeding 
local blood flow which resulted in painful crisis until spontaneous resolution of vaso­
occlusion. Hereafter the critical role of the endothelial cells (ECs), adhesion molecules, 
leukocytes and platelets in the pathophysiology of vase-occlusion became increasingly 
clear. Cell adhesion, of both red and white blood cells, alter the hemodynamics of 
the microvasculature leading to a reduced flow rate promoting HbS polymerization, 
hence leading to occlusion of the microvasculature due to trapping of cells. Leukocytes 
contribute directly to the vase-occlusive process and elevated leukocyte counts are 
11 
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considered a risk factor for stroke, ACS and early SCD-related death.7•14•17 Many factors 
and processes have been shown to be involved in leading to endothelial activation, 
damage and dysfunction.6 
Painful crisis is most often the resultant of vase-occlusion and due to ischemia­
reperfusion injury multiple organ systems in SCD patients are affected leading to 
complications like osteonecrosis and ACS representing an important source of SCD­
associated morbidity and mortality. 
ENDOTHELIAL DYSFUNCTION 
Hemolysis and vase-occlusion lead to endothelial activation and dysfunction therefore 
inducing a chronic inflammatory state which is propagated by elevated blood levels 
of inflammatory cytokines, adhesion molecules and angiogenic factors.18•19 Here NO 
bioavailability, angiogenesis and vasoregulation, which is the regulation of vascular 
homeostasis by maintaining the balance between endothelial derived vasodilatory 
and vasoconstrictive factors, will be discussed in more detail. 
Nitric oxide bioavailability 
Sickling and unsickling of erythrocytes results in cell membrane damage leading 
to the release of hemoglobin. NO reacts with plasma hemoglobin producing 
methemoglobin and bio-inactive nitrate or iron-nitrosyl-hemoglobin resulting in 
irreversible NO scavenging pathways. A state of reduced endothelial NO bioavailability 
in SCD contributes to vasoconstriction and impairs downstream homeostatic vascular 
functions of NO like transcriptional repression of the cell adhesion molecules such as 
vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-
1, P-selectin and E-selectin. Due to hemolysis erythrocytes also release arginase. 
Arginase depletes plasma arginine by increasing the production of ornithine at the 
expense of citrulline production, thus further compromising NO bioavailability.20 
Hence, the normal balance of vasoconstriction to vasodilation is therefore skewed 
toward vasoconstriction, endothelial activation and proliferation.21 
Vasoregulation 
The endothelium regulates vascular homeostasis by regulating vasomotor tone, 
blood flow, growth of vascular smooth muscle cells and local inflammation.22 In 
addition to their constitutive production of the major vasodilator, NO, the ECs also 
produce other vasodilators such as prostacyclin, as well as vasoconstrictors including 
endothelin-1, angiotensin II and prostaglandins.23 In SCD, the finely-tuned production 
of EC vasoregulators is imbalanced. As mentioned earlier it is recognized that SCD 
is characterized by a reduced bioavailability of NO contributing to an increase in 
vasoconstriction that is thought to play a role in occurrence of complications such 
as PHT,24 as well as vaso-occlusion. Asymmetric dimethylarginine (ADMA), which is 
an endogenous inhibitor of NO synthase, is thought to contribute to the reduced 
NO availability in SCD next to the increased arginase level and the increased amount 
of reactive oxygen species.25 Reinforcing the decrease in endothelial vasodilatory 
NO, upregulation of vasoconstrictive factor production in the endothelium has 
been reported in SCD. Elevated levels of plasma endothelin-1, a potent long-acting 
mediator of vasoconstriction that is produced by endothelial and vascular smooth 
muscle cells in response to inflammatory stimuli, hypoxia and shear stress, have been 
found during steady state in SCD and appear to increase further during crisis.26-28 
ANGIOGENESIS 
Angiogenesis is the result of highly orchestrated series of molecular and cellular 
events, resulting in the migration, proliferation and differentiation of ECs into newly 
formed capillaries which can subsequently develop into more mature vessels. The 
microvascular vessel tone and structure is regulated by several factors, of which NO is 
a key regulator. Exposure of ECs to low oxygen tension results in a profound decrease 
in endothelial NO synthase transcription corresponding with a fall in endothelial NO 
synthase protein level which leads to a co-ordinate impairment of production of 
NO.29 The importance of NO to the physiology of vasomotor and endothelial activity 
is exemplified during chronic shortage leading to human cardiovascular diseases 
associated to endothelial dysfunction.30-32 Chronic decreased NO bioavailability 
13 
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contributes to endothelial activation and vascular wall remodeling due to the ability 
of modulating the EC production and release of growth factors.33-36 Angiogenic factors 
and vasoactive peptides, such as erythropoietin, platelet derived growth factor-� and 
endothelin-1, are known to be released from a variety of cells due to prolonged or 
severe hypoxia. 
The vascular endothelium in healthy adults is normally quiescent, yet after 
endothelial injury circulating (ECs) are mobilized in order to take part in endothelial 
neovascularization. Endothelial progenitor cells (EPCs) are CD34+ endothelial 
hematopoietic cells which are mobilized from the bone marrow in order to contribute 
to re-endothelialization.37•38 Increased growth factor release such as stromal cell­
derived factor-1 is thought to be responsible for EPC mobilization by enhancing the 
homing of EPCs and augmenting neovascularization in ischemic tissue. Moreover 
increased circulating EPC counts are found in chronic inflammatory diseases such as 
coronary artery disease.39 
Endothelial activation and release of angiogenic factors play a role in the 
development of mature and stable vessels and also in the development of PHT, cancer 
and othervasculardiseases.40A1 In SCD increased levels ofadhesion molecule expression 
(ICAM-1, VCAM-1, P-selectin), inflammatory and anti-inflammatory cytokines (IL-6, IL-
8, TNF-a) have been described to contribute to the development of organ injury. Many 
key angiogenic proteins have been found to differ between sickle cell patients and 
healthy controls.6•42-44 The role of circulating angiogenic factors in the development 
of SCD-related complications is still to be elucidated. Due to a specific level profile of 
the angiogenic factors SCD patients have been postulated to be in a pro-angiogenic 
state of which the endothelial activation in combination with vase-constriction could 
contribute to unbalanced angiogenesis leading to organ dysfunction.11,19,4s,4s As of yet 
mainly the role of angiogenic factors in the pathophysiology of SCD-related PHT is 
being studied. Herein altered levels of placenta-like growth factor (PIGF), vascular 
endothelial growth factor (VEGF) and platelet derived growth factor levels, among 
others, have been suggested to be of importance in both children and adults.47 
Angiogenesis has also proven roles of importance in other complications that occur in 
SCD, such as retinopathy, Moyamoya syndrome and stroke. However, studies seeking 
to find relationships between serum/plasma concentrations of angiogenic proteins 
and the presence of SCD-related complications have been inconsistent in results. 
CLINICAL MANIFESTATIONS IN SCO 
Chronic hemolysis and recurrent vaso-occlusion are responsible for the clinical 15 
features of SCD due to progressive development of disabling organ damage such as 
PHT, ACS, stroke, osteonecrosis and renal failure.6 
Until birth the �-globin genes are inactive and the y-globin genes are responsible 
for the production of fetal hemoglobin (HbF), hence a neonate is asymptomatic since a 
major part of the total hemoglobin is HbF. As of 6 months the HbF level decreases and 
symptoms start to appear such as avascular necrosis resulting in shortening of a digit, 
splenic or hepatic sequestration, in which pooling of erythrocytes in a rapidly enlarging 
spleen or liver leads to acute aggravation of anemia leading to circulatory collapse. In 
all ages but mainly during childhood recurrent infarction of the spleen primarily leads 
to dysfunction and eventually, especially in HbSS, to functional asplenism. Patients 
with asplenism show an increased susceptibility to various infections, mainly with 
encapsulated bacteria such as pneumococci.48-50 Parvovirus B19 infection can result in 
acute worsening of anemia due to a total arrest of erythropoiesis by invading the red 
cell precursor. The increased life expectancy in SCD leads to an increment in chronic 
complications in adults affecting internal organs.51 
Acute painful crisis 
The most frequently seen complication and the most common cause of hospitalization 
is the acute painful crisis which can be triggered by infection, heavy physical exertion, 
high altitude and dehydration but which can also develop spontaneously.7•52•53 A 
painful crisis is generally the resultant of acute vaso-occlusion which in patients with 
SCD is caused by an increase of ischemic tissue injury resulting from the occlusion of 
microvascular beds by sickled erythrocytes. The pain most commonly involves the 
back, legs, knees, arms, chest and abdomen. 
An acute abdominal pain crisis can mimic an intra-abdominal process such as 
cholecystitis or appendicitis resulting in surgery. In the majority of cases during surgery 
16 
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no specific cause is identified and spontaneous resolution occurs. The frequency, 
severity, and duration of these crises vary considerably. 
Pulmonary hypertension 
In SCD and namely in homozygous sickle cell anemia, pulmonary complications such 
as PHT have emerged as a significant independent risk factor of early death yet the 
mortality rate and true prevalence have recently been challenged.B,13,54•56 Even more a 
recent study showed that the prevalence of PHT in SCD detected on echocardiographic 
screening has probably been overestimated.56 In former studies the prevalence of 
PHT in SCD when using Doppler echocardiography, with PHT defined as tricuspid 
regurgitant jet velocity of �2.5 m/s, is estimated to be 30% with a mortality rate of 
5.3%.B When using right heart catheterization, which in international guidelines is 
recommended as standard of care, the prevalence has recently been shown to be 6% 
with a mortality rate of 2%.56 
The pathogenesis of PHT in SCD is likely multifactorial and intravascular hemolysis, 
impaired NO bioavailability, altered endothelial function, continuous vase-occlusion 
in the micro-vasculature and ischemia-reperfusion injury are thought to play a role. 
Chronic lung injury may lead to fibrotic pulmonary parenchymal damage, hypoxia and 
a pulmonary vasculopathy. Nevertheless ACS, which is a potential cause of chronic 
lung disease and pulmonary fibrosis, is not associated with PHT.57 
Acute chest syndrome 
Next to PHT ACS is a very unique SCD-related complication which is the second most 
common cause of hospitalization and premature death. ACS also is the leading cause 
of admission to an intensive care unit in this patient population.5B The incidence of 
ACS is highest in children 2-4 years of age and, while gradually declining with age, 
remains common in adults.59 Severity varies, but 13% of patients require mechanical 
ventilation and 3% die.5B ACS can be defined as a presence of a new infiltrate not 
due to atelectasis, involving at least one complete lung segment, chest pain, fever 
and tachypnea. Current understanding of the pathophysiology is limited but ACS may 
be caused by airway infection, fat emboli or pulmonary infarction yet most cases 
develop during vase-occlusive crisis without a clear explanation.5B Also decreased NO 
bioavailability leading to vasoconstriction in the pulmonary vasculature and hemolysis 
are thought to be mechanisms of importance in the development of ACS.60 
TREATM ENT 
SCD is a devastating disease with acute and chronic manifestations. These complications 17 
may result in hospitalization and poor quality of life. Since the pathophysiology is not 
completely understood treatment is mainly symptomatic and preventive. The care 
of patients with SCD has undergone important advances in recent years. In western 
countries institution of newborn screening programs, provision of pneumococcal 
vaccination and prophylaxis with penicillin in childhood is administered and effects 
of efficacious drugs, such as hydroxycarbamide (also known as hydroxyurea) are 
better understood. New therapies and drugs such as gene therapy, administration 
of NO and L-glutamine, are currently being examined as possible alternatives for 
pharmacotherapy. They are at different stages of basic and clinical investigation. 
The concepts of individualized therapy and combination therapy have been further 
explored in more recent years, also offering promise to improve the care of patients 
with SCD.61 
Stem cell transplantation is the only curative therapy with an estimated mortality 
risk of 7-15% yet due to lack of suitable matched donors and the chronic use of 
immunosuppressive drugs with serious side effects the treatment is rarely used.62•63 
Painful crisis is the most frequently seen complication which patients often can 
manage at home by using pain medication like acetaminophen, non steroidal anti­
inflammatory drugs and codeine.64•65 When hospital administration is necessary for 
treatment of a painful crisis an underlying cause, such as an infection, should be 
sought and intravenous opioids, oxygen and fluids administered. 
In treating ACS the primary goal is to correct underlying factors that contribute 
to deoxygenation and reduction of the amount of HbS, ischemia and preventing 
(further) injury to the lung. In 30% of cases an infection was determined, hence once 
ACS has been diagnosed antibiotics are usually given although this does not seem to 
shorten the clinical course.66 Hydroxycarbamide is known to decrease the rate of ACS 
and blood or exchange transfusion has been shown to produce improvement.58 
For SCD-related PHT there is no proven treatment. Regular blood transfusion 
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and anticoagulation have been suggested.13·67 Prostacyclin analogues, endothelin-1 
receptor antagonist (Bosentan), phosphodiesterase-5 inhibitors (Sildenafil) and 
calcium channel blockers are being evaluated in the treatment of PHT in SCD. 
THES IS OUTL INE 
SCD is a complex and severe systemic disease in which hemolysis and vaso-occlusion 
are both known to result in endothelial activation leading to impaired angiogenesis. 
Angiogenesis is likely to be of importance in SCD-related (patho)physiology.6 
Nevertheless the factors important for the angiogenic response are not known and 
the importance of circulating angiogenic factors in the development of SCD-related 
complications remains to be elucidated. 
Therefore the aim of this present thesis is: 
1. To explore the role of angiogenesis in SCD-related complications. 
2. To study the role of specific factors that decrease NO bioavailability in SCD 
In this thesis chapter 2 and 3 address results of studies on pro- and anti-angiogenic 
factors, their possible role in maintaining the pro-angiogenic state as well as their 
relation to the presence of disease-related complications. In chapter 4 and 5 the role 
of circulating ECs is studied in SCD. Lastly the importance of ADMA, the endogenous 
inhibitor of NO-synthase, in the pathophysiology of SCD is set out in chapter 6, 7 and 
8. 
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ABSTRACT 
The anti-angiogenic factors soluble Fms-like tyrosine kinase (sFlt)-1 and soluble 
endoglin (sEng) have been shown to be of importance in angiogenesis by sequestering 
and inhibiting vascular endothelial growth factor (VEGF), placenta-like growth factor 
(PIGF) and transforming growth factor-�1 signaling. Given the potential role of 
angiogenesis in the pathophysiology of sickle cell disease (SCD)-related complications, 
serum levels of sFlt-1 and sEng were determined in SCD patients and controls. Both 
sFlt-1 (p = 0.002) and sEng (p = 0.004) were elevated in patients during clinically 
asymptomatic SCD with no further increment during painful crisis. These data suggest 
that sFlt-1 and sEng may be important in the regulation of angiogenesis in SCD. 
INTRODUCTION 
Next to vaso-occlusion-induced ischemic organ damage, the formation of abnormal 
blood vessels (e.g. sickle retinopathy or Moyamoya disease) and the process of 
vascular remodeling (pulmonary hypertension) contribute significantly to sickle cell 
disease (SCD)-related morbidity.1 Such pathologic processes are, at least in part, 
driven by hypoxia and inflammation-induced angiogenesis. Angiogenesis is a well­
orchestrated process determined by the relative levels of pro- and anti-angiogenic 
proteins, as well as target cell receptor expression.2 We have recently shown elevated 27 
angiopoietin (Ang)-2 levels in relation to Ang-1 and vascular endothelial growth factor 
(VEGF) levels in patients with SCD, suggesting a pro-angiogenic state.3 
Several studies have shown the importance of the anti-angiogenic factors soluble 
Fms-like tyrosine kinase (sFlt-1) and soluble endoglin (sEng) in disease states associated 
with abnormal angiogenesis such as preeclampsia.4 sFlt-1 is a soluble form of VEGF 
receptor-1, which binds to and sequesters circulating free VEGF and free placenta-like 
growth factor (PIGF), thereby neutralizing their pro-angiogenic effects.4 sEng is the 
soluble form of the transforming growth factor (TGF)-� co-receptor Eng and is known 
to bind and inhibit TGF-�1 signaling.4 TGF-�1 is also a pro-angiogenic protein, and 
the TGF-� pathway has been associated with several major SCD-related complications 
such as pulmonary hypertension,5 leg ulcers,6 stroke and priapismY Given the new 
insights into angiogenesis as a factor of importance in the pathophysiology of SCD, we 
set out to characterize serum profiles of sFlt-1 in relation to VEGF and PIGF levels, as 
well as sEng levels in SCD patients during the clinically asymptomatic state and during 
acute vaso-occlusive crises. 
PATIENTS AND METHODS 
Patients 
Fourteen HbSS and 9 HbSC patients were consecutively included in this study. Blood 
samples were drawn in clinically asymptomatic state and during a vaso-occlusive 
crisis (defined as an episode of acute pain in the abdomen and/or extremities not 
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otherwise explained) from the same patients. None of the patients were on any kind 
of treatment except for folic acid. Thirty-four HbAA blood donors served as healthy 
controls. Written informed consent was obtained from patients and controls. This 
study was approved by the local ethical review board and conducted in agreement 
with the Helsinki Declaration of 2000. 
Reagents 
Blood was collected and serum prepared according to standard procedures and frozen 
at -80°C. Serum sFlt-1, sEng, VEGF and PIGF levels were measured by enzyme-linked 
immunosorbent assay (R&D Diagnostics, Minneapolis, Minn., USA) according to the 
manufacturer's instructions. 
Data Analysis and Statistics 
For multiple group comparisons of continuous variables, the Kruskal-Wallis test was 
employed. For paired sample analysis (clinically asymptomatic state compared to 
vaso-occlusive events), the Wilcoxon signed-rank test was used. p Values .$_0.05 were 
considered statistically significant. The Statistical Package for Social Sciences (version 
14.0, SPSS 1"C, Chicago, Ill . ,  USA) was used. 
RESULTS 
Serum levels of sFlt-1 and sEng were elevated in the asymptomatic state of both HbSS 
and HbSC patients compared with healthy controls (Table 1), but did not increase 
further at presentation during a painful crisis. In both the asymptomatic and vaso­
occlusive phase, VEGF and PIGF serum levels were comparable to controls (Table 1), 
even though VEGF levels increased in a significant number of HbSC patients during 
vaso-occlusive crises (p = 0.02, data not shown). 
Table 1 I Anti- and pro-angiogenic factors in clinically asymptomatic patients and 
healthy controls 
HbSS (n = 14) HbSC (n = 9) Control (n = 34) p-value 
sEng, ng/ml 6.3 (5.4 - 8.4) 6 .1 (3.9 -7.1) 4.1 (3.4 -5 .1) <0.01 
sFlt-1, pg/ml 215 (130 - 314) 182 (116 - 294) 21 (0 - 154) <0.01 
VEGF, pg/ml 344 (176 - 678) 146 (81 -492) 261 (143 - 453) 0.51 
PIGF, pg/ml 11.3 (7.6 - 14.2) 8.9 (4.2 -12.7) 10.7 (7.8 - 13.8) 0.63 
Data are shown as medians with interquartile ranges. The Kruskal-Wallis test was 
employed for between group analysis. 
DISCUSSION 
The process of angiogenesis may play a role in determining the rate o f  tissue 
regeneration and in the development of specific SCD-related complications such as 
sickle retinopathy, Moyamoya disease and pulmonary hypertension. In SCD, enhanced 
Ang-2 levels in the presence of unaltered VEGF levels suggest a pro-angiogenic state.3 
Circulating levels of the anti-angiogenic factors sFlt-1 and sEng were determined 
in SCD patients since they emerged as important inhibitors of angiogenesis. In 
this study, serum sFlt-1 and sEng levels were statistical ly significantly increased 
in clinically asymptomatic SCD patients compared with healthy controls, with no 
further increments during an acute vaso-occlusive crisis. sFlt-1 has been implicated 
in pathological angiogenesis and inflammation by sequestering circulating free VEGF 
and PIGF.4 In preeclampsia, elevated sFlt-1 levels contribute to endothelial dysfunction 
and the development of renal failure and proteinuria. The sFlt-1 elevations in our 
patients could be hypoxia driven via induction of hypoxia-induced factor (HIF)-la 
following continuous tissue hypoxia secondary to ongoing microvascular occlusion.9 
Neither free VEGF nor free PIGF serum levels were elevated in our patients. VEGF 
expression is upregulated by pro-inflammatory cytokines and hypoxia,10 and PIGF 
expression is induced by erythropoietin (EPO), 11 with VEGF and PIGF targeting the 
same receptors.10 Recently, it has been demonstrated that in preeclampsia free 
VEGF (and PIGF) levels decreased probably due to sequestration by elevated sFlt-1 
levels despite hypoxia-induced increments in total circulating VEGF levels,4 possibly 
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indicating that the lack of increments in free VEGF and PIGF during steady state in 
our patients also results from sFlt-1 sequestration. The potent anti-angiogenic role 
of sEng, a potential N-terminal cleavage product of the full-length TGF-13 co-receptor 
Eng, has recently been described.12 sEng is known to inhibit activated TGF-131 binding 
to its receptor on endothelial cells and its serum levels were significantly elevated in 
SCD patients during the asymptomatic state.13 We (and others) could not measure 
circulating TGF-131 as it is probably complexed to several inhibiting proteins and 
unable to bind to its receptors (data not shown).12 Locally generated active TGF-131 
is known to stimulate endothelial nitric oxide synthetase expression.12 The elevated 
sEng levels could, via local inhibition of TGF-131 signaling, therefore contribute to the 
recently recognized reduced NO bioavailability in SCD, 14 a factor now appreciated as a 
central factor in the development of major SCD-related complications. 
In evaluating both the role of sFlt-1 and sEng in SCD, consideration should be 
given to the fact that the increased absolute concentrations are (substantially) 
lower than those measured during preeclampsia, which could very well reflect the 
etiological differences of SCD-related angiogenic activity and chronic endothelial 
dysfunction, and angiogenesis and endothelial dysfunction during this pregnancy­
related complication. 
During a painful crisis, serum sFlt-1 levels did not further increase, in agreement 
with an in vitro model of placental hypoxia demonstrating HIF-la-regulated sFlt-
1 expression to be unaffected by intermittent hypoxic stress.9 Interestingly, Eng 
expression is also primarily regulated by HIF-la,15•16 and the unaltered levels during 
acute vaso-occlusive crises could be explained by the same mechanism. EPO is an 
important PIGF inducer and a trend to higher EPO levels was observed in a larger 
group of SCD patients during painful crises with a significant increment in PIGF 
levels.3•11 In this admittedly smaller group of patients, these findings could not be 
reproduced. During painful crises, VEGF did increase only in HbSC patients (data 
not shown). Lack of further increments in the measured factors does not exclude 
potentially important roles in the development of SCD-related complications, since 
evidence is accumulating that the development of organ damage and dysfunction is 
often not related to the occurrence of acute vaso-occlusive events.17•18 
Contrary to our findings, Mohan et al did not detect elevated sFlt-1 levels in their 
study on clinically asymptomatic SCD patients.19 However, comparison with our data is 
difficult since the authors do not discern between values for HbSS and HbSC patients 
(which may be substantial ly different according to our data). Furthermore, citrated 
plasma was employed (compared to serum), perhaps indicating a methodological 
basis for the observed discrepancies. 
In conclusion, our data indicate that, during the clinically asymptomatic state, SCD 
patients are characterized by increased serum levels of the anti-angiogenic factors 
sFlt-1 and sEng, further supporting the concept that SCD is characterized by an altered 
angiogenic state. The net effect of sFlt-1 and sEng inhibition of VEGF, PIGF and TGF-131 
on angiogenesis in SCD, as well as the potential of identifying patients at risk for 
specific complications by monitoring serum sF lt-1 and sEng levels (as was recently 
demonstrated for preeclampsia) will be the subject of further studies. 
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Angiogenic Factors in Sickle Cell Disease-Related Complications 
ABSTRACT 
Hypoxia induced angiogenesis plays an important role in the pathophysiology of sickle 
cell disease (SCD). In order to investigate the association of angiogenic factors with 
SCD-related complications we measured serum levels of angiopoietin {Ang)-1, Ang-2, 
vascular endothelial growth factor (VEGF), placenta-like growth factor (PIGF), soluble 
tunica intima endothelial kinase (sTie)-2, erythropoietin (EPO) and soluble vascular 
rr, cell adhesion molecule (sVCAM)-1 in a well defined SCD population. We analyzed 
� serum samples of 51 HbSS/HbS�0-thalassemia and 24 HbSC/HbSj3+-thalassemia 
6 patients in absence and presence of SCD-related complications such as pulmonary 
hypertension, retinopathy and stroke. The angiogenic profiles did not seem to differ 
36 
between patients with and those without complications. 
INTRODUCTION 
Endothelial cells (ECs) and angiogenic mediators play important roles in diseases such 
as cancer, pulmonary hypertension (PHT) and retinopathy.1•2 Angiogenesis is regulated 
by cytokines and angiogenic factors such as vascular endothelial growth factor 
(VEGF), angiopoietin (Ang)-1 and Ang-2. Endothelial receptor soluble tunica intima 
kinase (sTie)-2 binds angiopoietins with the relative Ang-1/Ang-2 levels in relation to 
VEGF levels determining the balance between vessel quiescence and angiogenesis.3 
These angiogenic factors favor angiogenesis when in the presence of VEGF Ang-2 is 
relatively increased to Ang-1, vessel quiescence is maintained when Ang-1 is relatively 
increased to Ang-2. Placenta-like growth factor (PIGF) is an erythroid cell-derived 
cytokine belonging to the VEGF family. Next to direct angiogenic effects PIGF release 
leads to monocyte activation resulting in not only VEGF release,4 but also increased 
gene expression of cytokines such as tumor necrosis factor-a, interleukin (IL)-1 and IL-
8.5 In addition to its hematopoietic role, erythropoietin (EPO) is also recognized as an 
angiogenic growth factor responsible for tumor growth progression.6 
Abnormal or disrupted angiogenesis likely plays a role of importance in the 
development of several sickle cell disease (SCD)-related complications. SCD is 
characterized by continuous EC activation, ongoing (low grade) tissue ischemia and 
continuously elevated EPO levels due to the hemolytic anemia, all factors known 
to induce or contribute to angiogenesis. Indeed, angiogenesis has proven roles of 
importance in several complications that occur in SCD, such as PHT, retinopathy, 
Moyamoya syndrome and stroke. Furthermore, many key angiogenic factors have 
been found to differ between sickle cell patients and healthy controls.1-11 
However, studies seeking to find relationships between serum/plasma 
concentrations of angiogenic proteins and the presence of SCD-related complications 
have been inconsistent in results.12 We therefore set out to compare serum levels 
of several important angiogenic proteins in relation to the presence or absence of 
disease-related complications in a well defined SCD patient cohort. 
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PATIENTS AND METHODS 
Patients 
Forty-six HbSS, 18 HbSC, 6 HbSl3°-thalassemia and 6 HbSW-thalassemia adult sickle 
cell patients cared for at the Department of Internal Medicine of the Sint Elisabeth 
Hospital (Curac;ao), the Slotervaart Hospital (Amsterdam, The Netherlands), and 
the Department of Hematology of the Academic Medical Centre (Amsterdam, The 
CY) Netherlands) were considered eligible. Written and informed consent were obtained 
� from all patients. This study was approved by the internal review board of the 
6 Academic Medical Centre and carried out in accordance with the principles of the 
38 
Declaration of Helsinki of 1975, as revised in 2000. 
SCD-related complications 
In the outpatient clinics adult patients are regularly screened for SCD-related 
manifestations as previously defined and reported: 13 Micro-albuminuria: urinary 
albumin (mg/I) to urinary creatinine (mmol/I) ratio >3.5 (males)/ >2.5 (females) 
confirmed with 24 hour urine collection with micro-albuminuria >30 mg/24 hours. 
PHT: tricuspid regurgitation jet flow velocity (TRV) �2.5 m/s in rest detected by 
Doppler echocardiography. PHT was considered absent when no or only trace TRV 
is detected. Mild PHT was defined as TRV 2.5-2.9 m/s and moderate to severe as 
TRV �3.0m/s. Retinopathy: presence of at least mild non-proliferative retinopathy. 
Cho/elithiasis: presence of gallstones (ultrasound) or previous cholecystectomy 
because of cholecystolithiasis. Acute chest syndrome (ACS}: defined as previously 
described occurring between January 2002 until January 2007.14 Symptomatic 
avascular osteonecrosis (AVN): local pain and reduced function documented 
osteonecrosis of the femoral or humeral head (hip or shoulder X-ray) or a history 
of surgical intervention for osteonecrosis. Leg ulcer: chronic ulcer of the ankle not 
otherwise explained. Priapism: spontaneous painful erection requiring hospital care. 
Stroke: history of stroke confirmed by Magnetic Resonance Imaging or Computerized 
Tomography. Painful crises: the cumulative number of admissions for painful crises 
(defined as typical musculo-skeletal/abdominal pain not otherwise explained) from 
January 2002 until January 2007 was used to categorize patients into 2 groups: 0-1 
painful crisis per year and 2 or more pa inful crises per year. 
Collection of blood samples 
Blood samples were collected during regular outpatient visits from the antecubital 
vein with a vacutainer® system. Whole blood samples were centrifuged at 1700g for 
10 min. Serum was collected and aliquots were stored at -70°C until further analysis. 
Laboratory determinations 
Serum Ang-1, Ang-2, sTie-2, VEGF, PIGF, EPO and soluble vascular cell adhesion 
molecule (sVCAM}-1 levels were determined by enzyme-linked immunosorbent assay 
according to manufacturer's procedures (R&D Diagnostics, USA). 
Statistical analysis 
As previously reported the most severe SCD genotypes (HbSS and HbSj3°-thalassemia) 39 
were grouped together, as were the relatively milder genotypes (HbSC and HbSW­
thalassemia}.15 Continuous data are presented as medians with their corresponding 
inter-quartile ranges (IQR). Between group statistical analysis were confined to 
comparisons where at least four cases were present per group, and organ damage 
had to be screened for in at least two years prior to study inclusion. Between 2 groups 
differences were tested with the Mann-Whitney U test. For correlation studies the 
Spearman correlation coefficient (r) was calculated. P-values <0.05 were considered 
statistically significant. Statistical analysis was performed by using Statistical software 
Package for the Social Science (SPSS}, version (SPSS 15.0., SPSS inc, Chicago, Ill , USA). 
RESULTS 
Patient characteristics are shown in Table 1. Apart from retinopathy other 
complications were rarely seen in the HbSC/HbSW-thalassemia group precluding 
further analysis in this group. Forty-six patients in the HbSS/HbSj3°-thalassemia group 
were consecutively screened for PHT with echocardiography as reported elsewhere 
this group consisted almost exclusively of patients with mild PHT.16 Only two patients 
had moderate to severe PHT with TRV levels of 3.0 and 3.5 m/s. 
In the HbSS/HbSj3°-thalassemia group serum sTie-2 concentrations were 
significantly decreased in patients with retinopathy (28.9pg/mL, 22.9-39 .3pg/mL) as 
opposed to those without (39pg/mL, 28.3-47.3pg/mL) (p=0.035}. In patients with PHT 
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and nephropathy sVCAM-1 levels were higher as opposed to patients without these 
complications (1053.Gng/ml, 792.1-1200.7ng/ml vs. 1342ng/ml, 937.5-1697.4ng/ 
m l, p=0.049 and 1637.2ng/ml, 1283.6-2241.Bng/ml vs. 1072ng/ml 792.1-1273.Gng/ 
m l, p=0.007, respectively). No other statistical ly significant differences were detected 
in measured parameters between patients with and without disease-related 
complications. 
Statistical ly significant correlations were detected between serum levels of Ang-1 
and sTie-2 (r
5
=-0.307, p=0.028), Ang-1 and Ang-2 (r
5
=-0.287, p=0.041), VEGF and EPO 
(r
5
=0.339, p=0.030). TRV was statistically significantly correlated to serum sVCAM-1 
levels (data not shown). No other statistically significant correlations were observed 
(data not shown). 
DISCUSSION 
Several studies have shown altered serum levels of angiogenic factors in patients with 
SCD as opposed to healthy controls, implying a role for (dysregulated) angiogenesis 
in the pathophysiology of SCD-related complications. In this study, apart from lower 
serum sTie-2 levels in the HbSS/HbSf3°-thalassemia group with sickle retinopathy, no 
relation of angiogenic factor levels to the presence of disease-related complications 
could be detected. 
Retinopathy occurs in greater frequency in double heterozygous forms of SCD 
which as of yet has not been explained by recent research.17·18 As was reported for 
proliferative diabetic retinopathy we measured lower sTie-2 concentrations in HbSS/ 
HbSf3°-thalassemia patients with retinopathy as opposed to those without.19 However, 
this was not the case in HbSC/HbSf3+-thalassemia patients and Mohan et al reported 
no significant increment of sTie-2 plasma levels in a heterogeneous group of sickle cell 
patients with retinopathy.20The different angiogenic profiles of HbSS and HbSC patients 
might lead to the increased frequency and different pathophysiology of retinopathy 
in these two sickle genotypes.8•21•22 The decreased sTie-2 level in HbSS patients is not 
correlated to Ang-2 or VEGF and decreased level or sustained blockage of the Tie-2 
receptor seemed to inhibit neovascularization.23•24 Hence, one might speculate that 
the decreased level of sTie-2 in retinopathy and the negative association of Ang-1 to 
sTie-2 a re more l ikely to have a protective role in the development of retinopathy in 
HbSS/HbS�0-thalassemia patients. 
Table 1 I Patient characteristics 
HbSS (N=37)/HbSW (N=14) HbSC (N=18)/HbSW (N=6) 
N N=51 N=24 
Age (years) 27 (21-47) 30 (23-38) 
Male:Female 15:36 13:11 
Complications % 
PHT 40 10 
Retinopathy 28 53 
Nephropathy 18 0 
Albuminuria 40 5 
Stroke 10 0 
Priapism 11 0 
Leg ulcers 10 0 
�2 crises/year 13 11 
ACS 37 10 
Ang-1 (pg/ml) 30655 (19750-46770) 20945 (12755-42405) 
Ang-2 (pg/ml) 5525 (3608-7260) 2910 (2017-3633) 
Tie-2 (pg/ml) 30 (21-42) 33 (27-41) 
VEGF (pg/ml) 485 (273-1204) 280 (224-650) 
PIGF (pg/ml) 14 (9-39) 14 (8-43) 
EPO (mlU/mL) 71 (35-123) 34 (14-51) 
sVCAM-1 (ng/mL) 1118 (847-1357) 719 (601-971) 
Demographics and laboratory parameters in SCD patients. Data are presented as 
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Angiopoietins are important angiogenic factors in the development of PHT.25 However, 
serum concentrations of Ang-1, Ang-2 and sTie-2 did not differ between patients with 
and without PHT. VEGF levels were also similar between patients with and without 
PHT, without a relation to the TRV (as was recently reported in pediatric sickle cell 
patients), even though elevated serum VEGF levels have been associated with severe 
PHT.26 As our patients were almost exclusively characterized by mild PHT we cannot 
exclude a relation of serum VEGF levels to severe PHT in SCD. Furthermore, several 
studies have shown a poor correlation between local VEGF expression and serum 
VEGF levels, indicating that VEGF serum levels might not accurately reflect local VEGF 
levels to which cells of the pulmonary microvasculature are exposed. Brittain et al 
recently reported an association of plasma PIGF to severe $CD-related PHT.11 In our 
42 patients with mild PHT no relation of serum PIGF to PHT was present. We do not 
believe that the use of serum instead of plasma has influenced the outcome negatively 
since higher PIGF levels were measured in serum compared to PIGF levels in plasma in 
a population of pregnant woman with and without preeclampsia.27 
We did not find a relation between EPO levels and TRV in our adult SCD population 
which is in concert with an earlier study.28 Recently in a pediatric SCD population a 
relation was found between EPO and TRV assuming a different pathophysiology in the 
development of PHT then in the adult population.29 
In a mice study a negative association was seen between Ang-1 and sTie-2 which 
has been suggested to have a protective role in the development of PHT. In mice this 
pathway promotes EC survival under stress.30 Our present data studied in humans 
with $CD-related mild PHT also showed a negative association between Ang-1 and 
sTie-2 yet the role of this negative association in the development of PHT in humans 
still remains to be determined. 
Taken together, these data show that serum profiles of angiogenic proteins 
do not differ between patients with and without specific $CD-related complications. 
Given the complexity of the angiogenic process and the often not yet defined or 
poor relation between serum profiles, tissue expression and signal transduction, 
these data do not imply that angiogenesis does not play a role of importance in 
the pathophysiology of SCD. Conceding the relatively small sample size, our data do 
indicate that disease severity monitoring with serum levels of angiogenic factors may 
not be of value, even though prospective studies with serial sampling and in SCD­
related severe PHT need to be performed in order to further address this issue. 
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Circulating Endothelial Cells: a Parameter of Organ Damage 
ABSTRACT 
Objective laboratory tools are needed to monitor developing organ damage in sickle 
cell disease (SCD). Circulating endothelial cells (CECs) are indicative of vascular injury. 
We determined whether elevated CEC can be detected in asymptomatic SCD with the 
Cell Search system and whether the CEC count is related to clinical and blood-based 
biomarkers of disease severity. Fifteen consecutive clinically asymptomatic HbSS 
patients and 15 matched HbAA controls were analyzed for CEC counts, laboratory 
parameters of disease severity (Hb, leukocyte counts, HbF%), plasma levels of 
markers for endothelial activation (sVCAM-1, vWF:Ag) and of endogenous inhibitors 
of nitric oxide synthase (asymmetrical dim�thylarginine [ADMA]). CEC counts were 
significantly higher in patients (12 cells/ml, IQR 8-29) as compared to controls (4 
cells/ml, 3-10) (p=0.007). CEC counts were significantly higher in patients with 
pulmonary hypertension (PHT) (p=0.015), and increased with increasing number of 
affected organs (0-4 involved organs, p=0.002). No significant correlations between 
CEC and any other laboratory parameter were detected. In conclusion, CECs could 
prove to be an important new tool for assessing developing vasculopathy and organ 
damage in SCD. 
INTRODUCTION 
Sickle cell disease (SCD) i s  a heterogeneous disorder characterized by  chronic 
hemolysis, increased susceptibility to infections and acute and chronic vaso-occlusive 
complications culminating in significant morbidity and early death. Both improved 
supportive care (timely vaccination, penicillin prophylaxis, blood transfusions) and 
rational drug therapy (hydroxyurea) have contributed to an increasing life expectancy 
of patients with SCD, with most patients in Western countries surviving into the fourth 
and fifth decades of life.1 With this, the impact of accumulating organ damage on 
patient outcome has become increasingly clear. Both the ongoing vaso-occlusive 
process with its acute exacerbations, as well as the sequelae of chronic intra-vascular 
hemolysis, results in continuous endothelial insults, ultimately leading to widespread 
organ damage. Evidence of endothelial perturbation in SCD comes from animal 
models and studies in humans demonstrating elevated blood levels of endothelial 
activation markers, endothelial dysfunction and increased numbers of circulating 
endothelial cells (CECs).2-5 
Large patient cohort studies have identified laboratory markers associated with 
the clinical course of SCD, such as hemoglobin concentrations, leukocyte counts, 
lactate dehydrogenase (LDH) levels and the fetal hemoglobin percentage (HbF%).6 
Such markers are however, neither sufficiently reliable in predicting developing organ 
damage in individual patients, nor are they suitable for monitoring the effect of 
therapeutics in daily clinical practice.7 Accurate objective laboratory parameters that 
reflect the rate of developing organ damage in SCD are therefore needed. Attempts 
to assess the value of monitoring endothelial activation markers in relation to SCD 
severity have been made.3 However, most endothelial activation markers are neither 
specific for endothelial cells (ECs) (e.g., also expressed on or originating from non-ECs), 
nor specific for endothelial damage or dysfunction.a Therefore, measuring CECs may 
be more accurate for studying in vivo endothelial damage as is demonstrated in other 
disease states characterized by endothelial injury.a CECs are elevated and activated in 
SCD,5 but their relationship to organ damage in SCD has not been reported. 
We performed a pilot study to determine circulating CEC numbers in SCD with a 
validated automated rare cell analysis system and to assess their relationship to SCD-
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related organ damage, laboratory markers of disease severity, markers of endothelial 
activation and plasma levels of the endogenous nitric oxide synthase (NOS} inhibitor 
asymmetric dimethylarginine (ADMA).9 
MATERIALS 
Patients 
Consecutive patients attending the outpatient hematology clinics of the Erasmus 
Medical Center (Rotterdam) and the Academic Medical Center (Amsterdam) were 
screened. Inclusion criteria were high performance liquid chromatography confirmed 
diagnosis of sickle cell anemia (HbSS) and age �18 years. Exclusion criteria were blood 
transfusions in the preceding three months, any acute SCD-related complication in 
the preceding 2 weeks, pregnancy, cancer, infection, and connective tissue diseases. 
Race, age, and sex matched blood donors served as controls (HbAA). Written 
informed consent was obtained from all subjects. This study was approved by the 
52 local Institutional Medical Ethical Review Boards and is in agreement with the Helsinki 
declaration of 2000. - 1 
Clinical data 
In the participating centers, sickle cell patients are screened for the presence of organ 
damage as recently defined and described.1° From chart review, the following SCD­
related complications were scored if assessed within one year of sample collection: 
Pulmonary hypertension (PHT): tricuspid regurgitation jet flow velocity (TRV) 2:2.5 m/s 
in rest detected by echocardiography. PHT was considered absent with no or trace TRV. 
Micro-albuminuria: urinary creatinine (mmol/L) to urinary albumin (mg/L) ratio >3.5 
(males)/>2.5 (females) confirmed with 24 hour urine collection (microalbuminuria >30 
mg/24 h). Retinopathy: presence of at least mild non-proliferative retinopathy. Leg 
ulcers: chronic ulcers of the ankle not otherwise explained. The number of admissions 
for treatment of a painful crisis and/or acute chest syndrome (ACS} in the year before 
sample collection was recorded. 
Sample collection 
Whole blood, ethylenediaminetetraacetic acid (EDTA) blood, citrated blood, and 
CellSave preserved blood (contains EDTA and a proprietary preservative, Veridex, 
Raritan, NJ USA) were collected by venipuncture. To avoid contamination with 
traumatically detached ECs, CellSave tubes were drawn last. 
CEC enumeration 
The CellTracks AutoPrep and CellSpotter Analyzer II System (both Veridex) were used 
to count CEC.9 Four milliliters (ml) of CellSave preserved blood was incubated with 
ferrofluids coupled to a monoclonal antibody (mAb) against CD146 (clone S-Endo 1), 
present on ECs, a subset of activated T-cells and melanoma cells. After enrichment, 
cells were stained with fluorochrome-conjugated mAb: phycoerythrin (PE)-conjugated 
CDlOS, present on ECs and certain leukocytes, allophycocyanin (APC)-conjugated 
CD45, a pan leukocyte marker, and the nuclear dye 4' 6-diamidino-2-phenylindole 
(DAPI). CECs were immunophenotypically defined as DAPI+, CD146+, co10s+ and 
CD4S·. 
Sample analysis 
Standard laboratory tests were performed according to local protocols. Serum 
levels of soluble vascular cell adhesion molecule (sVCAM)-1 were determined using 
Enzyme-Linked lmmunoSorbent Assay (ELISA) (R&D Systems, Minneapolis, MN). Von 
Willebrand Antigen (vWF:Ag) and vWF ristocetin cofactor activity (vWF:RCo) were 
measured in citrated plasma and EDTA plasma concentrations of arginine and ADMA 
were also determined.11•12 
Statistical analysis 
No published data on CEC distribution as determined with the methods above in SCD 
were available. Furthermore, no reports on CECs in relation to organ damage in SCD 
were available and thus the number of CECs that are clinically relevant in relation to 
organ damage in SCD is presently unknown. Therefore, in this pilot study, a power 
calculation was not performed. Between group differences were assessed with the 
Mann-Whitney U test. Trends within ordered groups of non-parametric data were 
53 
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assessed using Cuzick's test for trends.13 For correlation studies Spearman's rank 
correlation coefficient (r) was determined. Statistical significance was considered 
with p<0.05 (STATA statistical software package 10, StataCorp, College Station, TX, 
USA). 
RESULTS 
Results of all measured parameters are shown in Table 1. CEC counts were significantly 
higher in sickle cell patients. Also, CEC counts were higher in sickle cell patients with 
PHT as opposed to patients without PHT, with no significant differences observed in 
relation to other forms of organ damage (Fig. 1). CEC counts increased significantly 
with increasing numbers of affected organs (Fig. 2). CEC counts were not related to 
painful crises (data not shown) and no acute chest syndromes or strokes had occurred 
in the year prior to CEC determination. CEC counts did not differ between patients on 
hydroxyurea and those who did not use hydroxyurea (data not shown). Additionally, 
no effect of hydroxyurea was observed on any of the other measured parameters 
(data not shown) in this cross sectional study. No statistically significant correlations 
were detected between CEC counts and hemoglobin concentrations, leukocyte 
counts, LDH concentrations or HbF% (data not shown) or any of the tested markers 
of endothelial activation (Fig. 3). Additionally, no significant correlations were found 
between CEC numbers and plasma arginine or ADMA concentrations in either healthy 
controls (r
5
=-0.13, p=0.64) or sickle cell patients (rs =0.05, p=0.88). 
Table 1 I Patient characteristics and laboratory data . 
HbAA (n = 15) HbSS (n = 15) p-va lue 
Age 24 (21 - 28) 24 {21 - 28) 
Gender {M:F )  4:14 4:14 
Hemoglobin (g/L) 14.1 {13.1 - 15.9) 8.7 (7.4 - 10.0) <0.0001 
Leukocytes {x109 /L) 6.7 {5.8 - 7.3) 8.7 {7.2 - 11.1) 0.003 
LDH ( IU/L) 144 (139 - 151) 487 {392 - 630) <0.0001 
Creatinin (µmol/L) 75 {55.6 - 95.6) 52 {49 - 57) <0.0001 
HbF {%) < 1.0% 7.7 (4.4 - 10) <0.0001 
Hydrea use (yes:no) NA 5 :10 
CEC (cells/ml )  4 (3 - 10) 12 {8 - 29) 0.007 
vWF:Ag ( IU/mL) 0.95 (0.81 - 1.44) 2.01 {1.23 - 2.51) 0.002 
vWF:Rco { IU/ml) 0.96 {0.74 - 1.25) 1.54 {1.20 - 1.95) 0.007 
6 
VCAM-1 (ng/ml) 921 (765 - 1050) 1879 (1398 - 2568) 0.0001 
ADMA (µmol/L) 0.42 (0.39 - 0.45) 0.70 {0.59 - 0.80) <0.0001 55 
Arginine (µmol/L) 80.8 (72. 7 - 90.9) 79.4 (53.0 - 88.7) NS 
Data are shown as medians and corresponding interquartile ranges. NS = not significant. 
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Fig 2. I Relation of CEC and the extent of organ involvement. The significance of 
trends in CEC counts with increasing organ involvement was assessed using Cuzick's 
test for trends. 
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Fig 3. I Correlation of CEC and vWF:Ag and sVCAM-1 levels in patients and controls. 
Healthy controls: CEC vs. vWF:Ag: r, = -0.14. p = 0.61. CEC vs. sVCAM-1: r, = -0.28. p = 
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DISCUSSION 
Continuous endothelial perturbation culminates in significant organ damage in 
SCD, and accurate monitoring of this process could be of great value in the study 
and management of SCD. We detected elevated CEC counts in the same range as 
previously reported in clinically asymptomatic sickle cell anemia patients using a 
validated automated CEC detection assay developed to overcome shortcomings of 
assays based on manual enrichment known to be susceptible to cell loss and to have 
low reproducibility.5•14 CEC counts appeared to be highest in those patients with most 
extensive organ damage. Importantly, patients with minimal organ involvement were 
characterized by CEC counts comparable to control values. No significant relation was 
observed between CEC counts and laboratory markers of disease severity, nor to crisis 
frequency. 
Direct EC injury by rigid sickled erythrocytes, high arterial vascular wall shear 
stress,8 neutrophil degranulation, present even in the clinically asymptomatic state of 
SCD,15 all likely contribute to the detachment of EC from the vessel wall. EC apoptosis 
can also lead to elevated CECs,8 however previous work on sickle cell CECs and plasma 
VEGF levels was suggestive of an anti-apoptotic tone.16 
Elevated blood levels of sVCAM-1 and vWF:Ag indicate EC activation in SCD, 
with further increments occurring during acute vaso-occlusive events.3•17•18 Levels of 
sVCAM-1 are related to hemolytic rate and either directly or indirectly to SCD-related 
complications associated with a high hemolytic rate, such as PHT and leg ulcers.3•19 
Also, sVCAM-1 levels have been associated with endothelial dysfunction in SCD 
as well .20 Neither sVCAM-1 nor vWF :Ag correlated significantly to CEC counts. EC 
activation was manifested even in patients with minimal organ damage, whereas CEC 
counts were comparable to controls in these patients. Importantly, these data suggest 
that the extent of EC activation/dysfunction is not necessarily related to the extent of 
EC damage and detachment in SCD. 
Recently ADMA has been recognized as an important contributor to the 
characteristically reduced nitric oxide bioavailability of SCD and its plasma level may 
be an important biomarker of disease severity, with associations reported to PHT 
and mortality in adult sickle cell patients.21•22 Plasma levels are elevated in SCD and, 
likely via NOS inhibition, contribute to endothelial activation.21 However, ADMA levels 
were not significantly associated to CEC counts in either patients or controls, perhaps 
suggesting that elevated ADMA levels contribute primarily to endothelial activation 
but not to endothelial damage. 
Several shortcomings should be addressed when interpreting these data. Firstly, 
our sample size was small, precluding multivariate analysis. Evidently, these findings 
are preliminary, but the differences in CEC counts between patients without organ 
damage and those at the other end of the spectrum with all organs affected can 
be clearly appreciated. Secondly, several clinical complications did not occur in our 
patients (e.g. acute chest syndromes) and some forms of organ damage were not 
screened for (e.g. silent ischemic brain injury). Also, we did not monitor patients after 
blood sampling, so we cannot exclude that acute events were developing at the time 
of sampling, possibly affecting CEC numbers. Lastly, as we did not characterize the 
phenotype of CECs, their vascular origin is unknown. 
In conclusion, these preliminary data show the feasibility of the employed 
technique for measuring CEC in SCD. Our findings suggest a possible relation of CEC 
counts to SCD-related organ damage, and CECs do not seem to be associated with 
either traditional or novel biomarkers of disease severity. Prospective studies in large 
patient cohorts addressing chronic organ damage, acute complications and the effect 
of established therapeutics (e.g. red cell transfusion and hydroxyurea) in relation to 
longitudinal CEC determinations are warranted to analyze whether CEC can be used 
as a reliable parameter to monitor developing organ damage in SCD. 
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ABSTRACT 
Inflammation and angiogenesis are of importance in the pathophysiology of sickle 
cell disease (SCD). Recently, the chemokine stromal-derived factor-1 (SDF-1) has 
been shown to be a key mediator of angiogenesis and inflammation. In this study 
we determined serum SDF-1 levels in consecutive adult sickle cell patients during 
the cl inically asymptomatic state as well as during painful crises. Serum SDF-1 levels 
were significantly elevated in HbSS/HbSW-thalassemia patients [n = 42; 5,177 pg/ml 
(2,438-7,246)] compared to HbSC/HbSW-thalassemia patients [n = 16; 2,405 pg/ml 
(1,365-3,047)] and healthy HbAA controls [n = 45; 2,894 pg/ml (2,577-3,334)] (p = 
0.001). No significant increments were observed during painful crises (n = 40). SDF-1 
levels were significantly higher in SCD patients with pulmonary hypertension (PHT) 
compared to patients without PHT. Elevated circulating SDF-1 levels occur in patients 
with SCD and may play a role in the pathophysiology of SCD-related PHT. 
INTRODUCTION 
Sickle cell disease (SCD} is a severe hemoglobinopathy characterized by an increased 
susceptibility to infections, chronic hemolytic anemia and continuous microvascular 
occlusion with acute exacerbations leading to accumulating organ damage and 
a decreased life expectancy.1 Both the vaso-occlusive process and intra-vascular 
hemolysis lead to a complex pathophysiological process characterized by endothelial 
activation, 2 decreased nitric oxide bioavailability and a recently recognized pro­
angiogenic state.3•7 Elucidation of the complex pathophysiology of SCD is an area of 
active research in order to identify potential parameters for objectively monitoring 
disease activity as well as new potential targets for therapy. 
The chemokine stromal-derived factor-1 (SDF-1/CXCL12} and its receptor 
CXCR4 (CD184} have recently been shown to be key mediators of angiogenesis and 
inflammation.8•9 Next to direct angiogenic effects, the SDF-1/CXCR4 axis is critically 
involved in hematopoietic stem cell/endothelial progenitor cell (EPC} recruitment to 
neo-angiogenic niches supporting the revascularization process of injured or ischemic 
tissue.9 In the context of hematopoietic stem cell transplantation, this knowledge has 
led to promising new and effective stem cell mobilization procedures by using CXCR4 
antagonists. 65 
Endothelial cells and pericytes (including smooth muscle cells} express both SDF-
1 and CXCR4, which are up-regulated by tissue damage and hypoxia, factors that 
readily occur in SCD.10·11 The SDF-1/CXCR4 axis is also involved in endothelial adhesion 
molecule (such as VCAM-1) induction and in platelet activation, 12•13 which are both 
important in SCD pathophysiology.11 Given the above, we set out to examine circulating 
SDF-1 levels in SCD patients during the clinically asymptomatic state, as well as during 
a painful crisis. Also, SDF-1 levels were studied in relation to the presence of chronic 
SCD-related complications. 
I./) .... 
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MATERIALS 
Patients 
Adult sickle cell patients cared for at the Department of Internal Medicine of the 
Sint Elisabeth Hospital (Cura�ao, Netherlands Antilles), the Slotervaart Hospital 
(Amsterdam, The Netherlands) and the Department of Hematology of the Academic 
Medical Center (Amsterdam, The Netherlands) were considered eligible. Blood 
samples were drawn from consecutively included patients during regular outpatient 
clinic check-ups as well as during acute painful sickle cell crisis. Blood bank donors 
served as healthy controls. Written and informed consent was obtained from all 
patients as well as controls and parents/legal guardians when appropriate. This study 
was approved by the internal review board of the Academic Medical Center and 
carried out in accordance with the principles of the Declaration of Helsinki of 1975, 
as revised in 2000. 
o. SCD-Related Manifestations 
6 In the outpatient clinics adult patients are regularly screened for SCD-related 
manifestations as previously defined and reported.14 Microalbuminuria: Urinary 
66 creatinine (mM) to urinary albumin (mg/I) ratio >3.5 (males) or >2.5 (females) 
confirmed with 24 h urine collection with micro-albuminuria >30 mg/24 h. Pulmonary 
hypertension (PHT): Tricuspid regurgitation jet flow velocity 6 2.5 m/s in rest detected by 
Doppler echocardiography. PHT was considered absent with no or only trace tricuspid 
regurgitation jet flow velocity. Retinopathy: Presence of at least mild non-proliferative 
retinopathy. Acute chest syndrome (ACS}: Defined as previously described occurring 
between January 2002 and January 2007. Symptomatic avascular osteonecrosis: Local 
pain and reduced function documented osteonecrosis of the femoral or humeral head 
(hip or shoulder X-ray) or a history of surgical intervention for osteonecrosis. Leg ulcers: 
Chronic ulcers of the ankle not otherwise explained. Priapism: Spontaneous painful 
erection requiring hospital care. Stroke: History of stroke confirmed by magnetic 
resonance imaging or computerized tomography. Pain rate: Pain rate was assessed by 
calculating the cumulative number of admissions for painful crises (defined as typical 
musculoskeletal/abdominal pain not otherwise explained) from January 2002 until 
January 2007 and categorizing patients into 2 groups (0-1 painful crisis per year and 
2 or more painful crises per year). Between-group statistical analysis was confined to 
comparisons where at least 4 cases were present per group and organ damage had to 
be screened for at least in the 2 years prior to study inclusion. 
Laboratory Parameters 
Serum SDF-1 levels were determined according to manufacturer's procedures (R&D 
Systems, Minneapolis, Minn., USA). All standard laboratory data were obtained 
during routine outpatient visits at least 4 weeks after the last acute disease­
related complication and at least 3 months after last blood transfusions. Fetal 
hemoglobin percentage was determined by cation exchange high-performance liquid 
chromatography. 
Statistical Analysis 
The most severe SCD genotypes (HbSS and HbSW-thalassemia) were grouped 
together, as were the relatively milder genotypes (HbSC and HbSW-thalassemia). 
Continuous data are presented as medians with their corresponding inter-quartile 
range. Between multiple group comparisons were analyzed employing the Kruskal­
Wallis test. Between 2 group differences were tested with the Mann-Whitney U test. 
For paired sample analysis the Wilcoxon signed rank test was used. For correlation 
studies the Spearman correlation coefficient (r) was calculated. p<0.05 were 
considered statistically significant (SPSS 12.0.2; SPSS inc, Chicago, 1 1 1., USA). 
RESULTS 
Patient and control characteristics as well as serum SDF-1 levels are shown in Table 1. 
Serum SDF-1 levels were elevated in the HbSS/HbS�0-thalassemia patients but did not 
increase further at presentation with a painful crisis (Table 1). When performing paired 
sample analysis in patients from whom both steady-state and painful crises samples 
were available, SDF levels did not differ either between the clinically asymptomatic 
state or at presentation with a painful crisis (increased in 4, decreased in 7, p=0.60). 
Analysis of serial SDF-1 determinations during evolution of painful crises revealed 
SDF-1 increments in 4 of 12 painful events (Fig. 1). In both HbSS/HbS�0-thalassemia 
and HbSC/HbSW-thalassemia patients, SDF-1 levels were higher in patients with PHT 
67 
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compared to those without PHT. SDF-1 levels were neither related to other forms of 
organ damage in our patients nor to hydroxyurea use (data not shown). Also, SDF-
1 was not significantly associated with hemoglobin levels, the percentage of fetal 
hemoglobin, total leukocyte counts or differentials (neither during steady state nor at 
presentation with a painful crisis) or lactate dehydrogenase levels (data not shown). 
SDF levels were not related to age in either patients or controls. SDF-1 levels in 
patients without PHT were also significantly elevated compared to controls (p=0.008). 
DISCUSSION 
SCD has recently been recognized to  be  characterized by  a pro-angiogenic state,4•7 
likely driven by continuous tissue damage and hypoxia due to both the ongoing vaso­
occlusive process as well as the sequelae of chronic intra-vascular haemolysis.15•16 The 
SDF-1/CXCR4 axis has been identified as a critical regulator of vascular remodeling and 
angiogenesis.9 Our results show circulating SDF-1 levels to be significantly elevated in 
steady-state HbSS/HbS13°-thalassemia patients with higher levels in patients affected 
by PHT, a recently recognized severe SCD-related complication.17 However, no clear 
association of circulating SDF-1 levels to acute painful sickle cell crisis could be 
demonstrated. 
Several regulatory pathways could contribute to the elevated SDF-1 levels in 
HbSS/HbS�0-thalassemia patients. SDF-1 expression in endothelial cells is induced 
by transcription factor hypoxia-inducible factor-la activation which is regulated 
by the nuclear factor-KB18•19 and increased nuclear factor- KB activity is typical in 
the context of the inflammatory state of SCD.2 Also, considering the reduction of 
NO bio-availability in SCD, 16 SDF-1 activity during angiogenesis has been shown to 
be intricately associated with NO bio-availability with,20 at least in animal models, 
endothelial NO synthase deficiency associated with increased SDF-1 expression.21 
In our patients, SDF-1 levels were significantly higher in patients with PHT 
compared to those without PHT. PHT is nowadays recognized as one of the most 
important chronic organ complications in adult SCD patients carrying a high risk of 
early death.22 Several lines of evidence in animal studies indicate a role of importance 
of SDF-1 in vascular remodeling in pulmonary arteries.23•24 Furthermore, an alternate 
Table 1 I Patient characteristics and circulating SDF-1 levels 
HbSS/HbSW-thalassemia• HbSC/HbSj3+-thalassemiab HbAA 
Patients 42 16 45 
Age 28 (21 - 38) 29 {24 - 38) 45 {36 - 63) 
Male/female 25 :17 8:8 33:12 
Hb, g/dl 9.0 (8.2 - 9.8) 11.2 {10.4 - 12.2) 14.1 {12.3 - 17.4) 
SDF-1, pg/ml steady statec 5.177 (2.438 - 7.246) 2.405 (1.365 - 3.047) 2.894 (2.577 - 3.334) 
SDF-1, pg/ml painful crisis 3.998 (2.605 - 5.623) 2.452 (1.956 - 4.734) NA 
Data are depicted as medians with corresponding interquartile ranges. 
• HbSS/HbS�0-thalassemia steady state vs. painful crisis (n = 34): p = 0.56; b HbSC/HbS�+-thalassemia steady state vs. painful crisis 
(n = 6) :  p = 0.64; c steady state HbSS/HbSW-thalassemia vs. HbSC/Hbs�+-thalassemia vs. HbAA: p = 0.001. NA = not applicable 
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SDF-1 receptor, CXCR7, has been identified which was recently shown to be up­
regulated in hypoxic human pulmonary microvascular endothelial cells accompanied 
by enhanced SDF-1 expression.23•25•26 Also, amelioration of hypoxia-induced PHT 
by statins was associated with down-regulation of circulating SDF-1 levels.27 Taken 
together, the association of SDF-1 to SCD-related PHT could suggest a potential role of 
SDF-1 in PHT pathophysiology. 
In light of the regulating mechanisms of SDF-1 expression it was surprising that 
SDF-1 levels did not increase significantly at presentation with a painful crisis. Both in 
vivo and in vitro experiments have shown SDF-1 expression to be strongly correlated to 
the severity of hypoxia with a relatively short production lag period, and bone marrow 
ischemia and infarction are central to the sickle cell crisis.9•28 Even though it remains 
unexplained at this time why SDF-1 did not increase at presentation with a painful 
crisis, our observations, including resolution of painful crises with increasing SDF-1 
levels ( Fig. 1), clearly argue against a role of importance in the uncomplicated painful 
crisis. SDF-1 levels increased with the development of an ACS in 1 patient and levels 
returned to baseline with clinical improvement, but none of the other patients with 
increasing SDF-1 levels developed an ACS. With the observation of SDF-1 increments 
during morphine-induced central hypoxia during 2 painful crises, these observations 
70 may suggest SDF-1 increments to be a biomarker linked to central hypoxia without 
pathophysiological importance in acute SCD-related complications. However, this 
needs to be specifically addressed in future studies. In interpretation of these data 
several factors need to be taken into account. Firstly, healthy controls consisted mainly 
of relatively older males. However, to the best of our knowledge, SDF-1 levels do not 
differ between males and females. Although the possibility cannot be eliminated 
based on our data, we did not detect a relationship of SDF-1 to age in the controls 
of patients. Secondly, paired sample analysis for steady state and painful crisis SDF-1 
levels was limited to a relatively small subgroup. Thirdly, given the small sample size, 
the findings pertaining to SDF-1 in relation to the presence of organ damage should 
be considered preliminary, and these need to be reproduced in a larger patient cohort 
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Fig 1. I Serial SDF-1 levels during painful crisis. At least 4 serial blood samples taken 
during evolution of a painful crisis were available to us during 12 crises occurring in 




and D ( ■ ;  remaining crises depicted with small symbol .A. ). Crises A and B occurred 71 
in the same patient {36-year-old HbSS female) and were uncomplicated painful 
crises except for several periods oxygen desaturation due to morph ine-induced 
hypoventilation. SDF-1 levels increased whereas the painful crises resolved. Crisis C 
occurred in a 46-year-old female HbS�0-thalassemia patient who was admitted with 
a painful crisis and developed a cholecystitis on day 6 and subsequently underwent 
urgent laparoscopic cholecystectomy. No post-operative follow-up samples were 
available for analysis. Crisis D occurred in a 19-year-old HbSS femal. On day 1 shortness 
of breath developed with an arterial oxygen saturation of 89% and bilateral pu lmonary 
infi ltrates. She was treated for an acute chest syndrome with exchange transfusion and 
started to recover on day 3. 
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Fig 2. I SDF-1 levels in relation to pulmonary hypertension (PHT) in SCD. Serum SDF-1 
levels in patients with and without PHT. SDF-1 levels were significantly h igher in HbSS/ 
HbSl3°-thalassemia patients with PHT compared to HbSS/HbSl3°-thalassemia patients 
without PHT (p = 0.02). In HbSC/HbS(3+-thalassemia patients with PHT SDF levels were 
also h igher compared to HbSC/HbSW-thalassemia patients without PHT (p = 0.01). 
In conclusion, we demonstrate for the first time elevated levels of SDF-1 in patients 
with SCD, further supporting the concept of SCD as a pro-angiogenic state. Further 
research of SDF-1, especially in relation to PHT, is warranted. Also, given emerging 
data on the role of EPC in SCD pathophysiology,29 the complex relationship between 
SDF-1 levels and circulating EPC numbers and function should also now be studied.30 
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ABSTRACT 
Plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous nitric 
oxide synthase inhibitor, are elevated in the clinically asymptomatic state of sickle 
cell disease (SCD). However, the role of ADMA during vase-occlusive complications 
has not been defined. ADMA concentrations were determined in HbSS (n=43) and 
HbSC (n=25) patients with healthy blood donors (HbAA) as controls. In the clinically 
asymptomatic state ADMA concentrations were elevated in sickle cell patients as 
compared to healthy controls (HbSS 0.70 µmol/L, HbSC 0.54 µmol/L, HbAA 0.39 
µmol/L) (p<0.001). Yet plasma ADMA concentrations did not increase further at 
presentation with a painful crisis implicating no role of primary importance during 
vaso-occlusive crises. 
INTRODUCTION 
Vasa-occlusion leads to accumulating ischemic organ damage and a decreased life 
expectancy in patients with sickle cell disease (SCD).1 Over the last yea rs the importance 
of a reduced nitric oxide (NO) bioavailability in the complex pathophysiology of 
several SCD-related complications such as pulmonary hypertension (PHT) and stroke 
has become increasingly clear.2•3 NO plays a central role in vascular homeostasis; it is 
a potent vasodilator which modulates endothelial activation, inhibits smooth muscle 
cell proliferation and migration, limits platelet aggregation, and ischemia-reperfusion 
injury.2 During the clinically asymptomatic state NO bioavailability is reduced in sickle 
cell patients due to the scavenging of NO by cell-free hemoglobin released from 
hemolyzed sickle erythrocytes,4 as well as due to increased arginase activity.5 During 
acute vase-occlusive events such as painful crises and acute chest syndromes a further 
decrease of NO bioavailability has been demonstrated.6•7 
We recently reported elevated plasma asymmetric dimethylarginine (ADMA) 
concentrations during the clinically asymptomatic state in SCD.8 ADMA, as well 
as NG,N'G_ dimethyl-L-arginine (symmetric dimethylarginine or SDMA) and NG­
monomethyl-L-arginine (L-NMMA), derive from irreversible post-translational 
methylation of guanidino nitrogens of arginine residues and are released as free amino 
acids upon proteolysis. ADMA competitively inhibits NO synthase (NOS), thereby 
reducing the conversion of arginine to citrulline thus limiting NO production. SDMA is 
not a NOS inhibitor, and the plasma concentration of ADMA is 10 times greater than 
that of L-NMMA. ADMA is degraded by dimethylarginine dimethylaminohydrolase 
(DDAH) which hydrolyzes ADMA to dimethylamine and citrulline. Hypoxia and 
elevated levels of pro-inflammatory cytokines may inhibit or down-regulate DDAH.9-12 
As both hypoxia and inflammation readily occur during vase-occlusive events in SCD, 
further increments in ADMA concentrations can be expected. We therefore set out 
to investigate whether ADMA concentrations increase during acute vase-occlusive 
complications in SCD. 
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MATERIALS AND M ETHODS 
Patients and controls 
Sixty-eight EDTA anticoagulated plasma samples were available from 52 sickle 
cell patients during the clinically asymptomatic state and 91 samples were available 
from 35 sickle cell patients during a painful crisis (35 samples taken at presentation 
with a painful crisis and 56 follow-up samples during evolution of a painful crisis). 
Blood samples were prospectively collected over a 7-year period at both the 
outpatient clinic and the emergency ward of the Sint Elisabeth Hospital in Cura�ao, 
the Netherlands Antilles. The clinically asymptomatic state was defined as being 
free of pain at least 4 weeks after the last acute SCD-related complication. A painful 
crisis was defined as an episode of acute pain in the extremities and/or abdomen not 
otherwise explained. 19 None of the patients were on any kind of treatment (apart 
from folic acid supplementation), nor had they received blood transfusions during the 
3 months prior to sample collection. Thirty-five race (but not age or sex) matched, 
blood donors served as healthy controls. Patients and controls gave written informed 
consent before sample collection. This study was approved by the local Ethical Review 
Board and is in agreement with the Helsinki Declaration of 2000. 
Samples and analysis 
Standard blood counts and clinical biochemistry (e.g. creatinine and lactate 
dehydrogenase (LOH) levels) were determined according to local protocols. EDTA 
anticoagulated blood samples were immediately centrifuged at 1700g for 10 
min. Plasma was collected and aliquots were stored at -70°C until further analysis. 
Plasma concentrations of arginine, ADMA, and SOMA were measured employing 
high-performance liquid chromatography with fluorescence detection as previously 
described, with modified chromatographic separation conditions.20•21 The inter-assay 
and intra-assay coefficients of variation were <3% and <1.5%, respectively, for all 
compounds. The upper limits (P97.5) of the reference range are 0.63 and 0.73 µmol/L 
for ADMA and SOMA, respectively.22 
Data analysis and statistics 
All data are presented as medians with corresponding interquartile ranges. For 
between multiple group comparisons the Kruskal-Wallis test was employed. The 
Mann-Whitney U-test was used for comparison between two groups. For paired 
sample analysis the Wilcoxons' signed rank test was used. Statistical software Package 
for the Social Science (SPSS), version 14.0, SPSS inc, Chicago, Ill (USA) was used and 
p<0.05 was considered statistically significant. 
RESULTS 
Plasma ADMA and SDMA concentrations were significantly elevated during the 
clinically asymptomatic state in both HbSS and HbSC patients as compared to healthy 
controls (Table 1). At presentation with a painful crisis, plasma ADMA concentrations 
did not increase further in HbSS or HbSC patients, but in HbSS patients the arginine/ 
ADMA ratios significantly decreased due to significant reductions in arginine 
concentrations (Table 2). Samples were available of 14 patients in both the clinically 
asymptomatic state and at presentation with a painful crisis. No statistically significant 
change in ADMA, arginine or arginine/ADMA could be detected in paired sample 
analysis (data not shown). Also, no consistent pattern could be detected of ADMA and 
arginine in four patients of whom at least four serial samples were available during 
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Table 2 I ADMA, SOMA and Arginine concentrations in the clinically asymptomatic state and at presentation with a painful crisis 
HbSS HbSC 
Asymptomatic state Painful crisis Asymptomatic state Painful crisis 
(n = 33) (n = 24) p-value (n = 19) (n = 11) p-value 
ADMA 
(µmol/L) 0.70 (0.63 -0.83) 0.66 (0.59 - 0.77) 0.5 0.54 (0.47 - 0.58) 0.55 (0.49 -0.61) 0.91 
Arginine 
(µmol/L) 58.5 (39.5 -79) 52.3 (37.S -70.8) 0.01 70.8 (59.8 - 80.4) 58.4 (37 .1 -91.4) 0.4 
Arginine/ 
ADMA ratio 80.5 (55.4 - 109.2) 71.0 (53.4 - 108.2) 0.03 147.2 0 (107.9 - 168.9) 104.3 (68.0 - 162.8) 0.29 
SDMA 
(µmol/L) 0.55 (0.45 -0.76) 0.51 (0.43 - 0.65) 0.6 0.49 (0.43 - 0.55) 0.51 (0.43 - 0.61) 0.58 
Data are depicted as median with interquartile ranges. The Mann-Whitney U test was employed for between group analysis. 
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DISCUSSION 
Elevated plasma ADMA concentrations lead to a reduced NO bioavailability through 
NOS inhibition and ADMA is known to be involved in several vascular disease states 
such as atherosclerosis, and preeclampsia.11 In this study, we determined whether 
ADMA concentrations increase during painful crises in SCD. 
As expected, plasma ADMA concentrations were higher in sickle cell patients 
as compared to healthy controls, with highest values detected in HbSS patients. No 
changes were observed in the absolute ADMA concentration (or SDMA concentration) 
at presentation with a painful crisis, but a significant decrease was seen in the arginine/ 
ADMA ratios in HbSS patients at presentation with a painful crisis due to a decrease in 
the plasma arginine concentration (likely as result of increased NOS and/or arginase 
activity).2 No clear pattern of ADMA or arginine could be detected with either paired 
sample analysis or with analysis of serial measurements. Therefore, a primary role of 
ADMA in the pathophysiology of the painful sickle cell crisis seems unlikely based on 
these findings. 
The main pathway of ADMA metabolism is degradation by DDAH,12 with a 
small fraction of ADMA excreted by the kidneys. As DDAH is inhibited during an 
inflammatory response,9 we would have expected plasma ADMA increments during 
painful crises. Why this does not seem to occur is not clear at this time. All sickle cell 
patients immediately receive oxygen, intravenous morphine, and saline at admission 
to the emergency ward prior to blood sample collection. Usually samples are collected 
within an hour upon arrival at the emergency ward. Hypoxia leads to DDAH down­
regulation, 10 but during an uncomplicated painful crisis, hypoxia is unlikely to occur 
to a significant extent in the lungs, kidney or liver (organs characterized by DDAH 
activity), perhaps in part explaining the lack of ADMA increments during sickle cell 
crisis. Furthermore, it is unknown whether oxygen supplementation increases DDAH 
activity. Even if this would be the case, it is unlikely that this would lead to ADMA 
reduction on such short notice. It is also unlikely that saline administered to our 
patients before sample collection (250 cc at most) has led to ADMA dilution, thereby 
masking an ADMA increment. As arginine inhibits DDAH activity, 13 the documented 
arginine reduction could in part explain the lack of ADMA increments. 
It is unlikely that reduced renal function is the sole explanation for the increased 
ADMA concentration in SCD during the clinically asymptomatic state, as SDMA, 
which is mainly cleared by renal excretion, 12 was not elevated to the same extent 
as ADMA. Furthermore, even though serum creatinine levels overestimate renal 
function in SCD, 14 creatinine concentrations were higher in healthy controls as 
compared to sickle cell patients. Plausible causes of elevated ADMA concentrations 
in SCD may be decreased DDAH activity and increased release of free ADMA (and 
SDMA) by proteolysis associated with the increased erythrocyte turnover (ADMA 
concentrations are reported highest in sickle cell patients with lowest hemoglobin 
concentrations).8 Furthermore, SCD is characterized by chronically elevated vascular 
wall shear stress15 which is known to induce expression of endothelial type-I protein 
arginine methyltransferase, a catalyst of arginine methylation.16 
In interpreting these data several limitations should be considered. Firstly, paired 
sample analysis was possible in a limited number of patients and the sample size 
of our study was relatively small. Secondly, ADMA concentrations are increased in 
primary PHT and PHT occurs in approximately 30% of adult sickle cell patients.17·18 At 
the time these samples were drawn it was unknown if patients had PHT. Even though 
it is likely that several patients would have had PHT, the role of ADMA in SCD-related 
PHT is not known. Therefore, a potential confounding effect on the main results of this 
study is currently unclear. Thirdly, most healthy controls were male and older than the 
patient group. Even though plasma ADMA concentrations are known to be higher in 
post menopausal women than in men and increase with age, this does not influence 85 
our main findings. 
In conclusion, plasma ADMA concentrations are elevated in patients with SCD but 
do not seem to increase further at presentation with a painful crisis, arguing against a 
role of primary importance of ADMA in the painful sickle cell crisis. 
ACKNOWLEDGEM ENT 
We gratefully acknowledge the expert technical assistance of Sigrid de Jong. 
86 
Asymmetric Dimethylarginine is Elevated in Sickle Cell Disease 
REFERENCES 
1. Stuart MJ, Nagel RL. Sickle-cel l  
disease. Lancet 2004; 364:1343-1360 
2. Rother RP, Bell L, H i l lmen P, 
Gladwin MT. The clinical sequelae 
of intravascu lar hemolysis and 
extracel lu lar plasma hemoglobin: A 
novel mechanism of human disease. 
JAMA 2005; 293:1653-1662 
3. Kato GJ, Hsieh M, Machado R, 
Taylor J 6th, Little J, Butman JA, 
et al. Cerebrovascular disease 
associated with sickle cel l  pu lmonary 
hypertension. Am J Hematol 2006; 
81:503-510 
4. Reiter CD, Wang X, Tanus-Santos J E, 
Hogg N, Cannon RO 3rd, Schechter 
AN, et al. Cell-free hemoglobin limits 
nitric oxide bioavailability in sickle-cel l  
disease. Nat Med 2002; 8:1383-1389 
5 .  Schnog J B, Jager EH,  van der Dijs FP, 
Duits AJ, Moshage H, Muskiet FD, 
et al. Evidence for a metabolic sh ift 
of arginine metabolism in sickle cel l  
disease. Ann Hematol 2004; 83:371-
375 
6. Stuart MJ, Setty BN. Sickle cell acute 
chest syndrome: Pathogenesis and 
rationale for treatment. Blood 1999; 
94:1555-1560 
7. Morris CR, Kuypers FA, Larkin S, 
Vichinsky EP, Styles LA. Patterns 
of arginine and nitric oxide in 
patients with sickle cell d isease with 
vasoocclusive crisis and acute chest 
syndrome. J Pediatr Hematol Oneal 
2000; 22:515-520 
8. Schnog JB, Teerlink T, van der Dijs FP, 
Duits AJ, Muskiet FA; CURAMA Study 
Group. Plasma levels of asymmetric 
dimethylarginine (ADMA), an 
endogenous nitric oxide synthase 
inhibitor, are elevated in sickle cel l  
disease. Ann Hematol 2005; 84:282-
286 
9. Nijveldt RJ, Teerl ink T, van Leeuwen PA. 
The asymmetrical dimethylarginine 
(ADMA)-multiple organ fa i lure 
hypothesis. Clin Nutr 2003; 22:99-104 
10. Mil latt LJ, Whitley GS, Li D, Leiper JM, 
Siragy HM, Carey RM, et al. Evidence 
for dysregulation of dimethylarginine 
dimethylaminohydrolase I in 
chronic hypoxia-induced pu lmonary 
hypertension. Circulation 2003; 
108:1493-1498 
11. Siroen MP, Teerlink T, Nijveldt RJ, Prins 
HA, Richir MC, van Leeuwen PA. The 
clinical significance of asymmetric 
dimethylarginine. Annu Rev Nutr 
2006; 26:203-228 
12. Wilcken DE, Sim AS, Wang J, Wang XL. 
Asymmetric dimethylarginine (ADMA) 
in vascular, renal and hepatic disease 
and the regulatory role of L-arginine 
on its metabolism. Mol Genet Metab 
2007; 91:309-317 
13. Wang J, Sim AS, Wang XL, Wilcken 
DE. L-arginine regulates asymmetric 
dimethylarginine metabolism 
by inhibiting dimethylarginine 
dimethylaminohydrolase activity in 
hepatic (HepG2) cells. Cell Mol Life Sci 
2006; 63:2838-2846 
14. Ataga Kl, Orringer EP. Renal 
abnormalities in sickle cell disease. 
Am J Hematol 2000; 63:205-211 
15. Belhassen L, Pelle G, Sediame S, 
Bachir D, Carvi l le C, Bucherer C, et al. 
Endothelial dysfunction in patients 
with sickle cel l  disease is related to 
selective impairment of shear stress 
mediated vasodilation. Blood 2001; 
97:1584-1589 
16. Osanai T, Saitoh M, Sasaki S, Tomita 
H, Matsunaga T, Okumura K. Effect 
of shear stress on asymmetric 
dimethylarginine release from 
vascular endothelial cel ls. 
Hypertension 2003; 42:985-990 
17. Kielstein JT, Bode-Boger SM, Hesse 
G, Martens-Lobenhoffer J, Takacs 
A, Fl iser D, et al. Asymmetrical 
dimethylarginine in idiopathic 
pulmonary arterial hypertension. 
Arterioscler Thromb Vase Biol 2005; 
25:1414-1418 
18. Gladwin MT, Sachdev V, Jison ML 
Shizukuda Y, Plehn J F, M inter K, et 
al. Pulmonary hypertension as a 
risk factor for death in patients with 
sickle cell disease. N Engl J Med 2004; 
350:886-895 
19. Serjeant GR, Ceulaer CD, Leth bridge R, 
Morris J, Singha! A, Thomas PW. The 
painful crisis of homozygous sickle 
cell disease: Clinical features. Br J 
Haematol 1994; 87:586-591 
20. Teerlink T, Nijveldt RJ, de Jong S, 
van Leeuwen PA. Determination 
of arginine, asymmetric 
dimethylarginine, and symmetric 
dimethylarginine in human plasma 
and other biological samples by h igh­
performance liquid chromatography. 
Anal Biochem 2002; 303:131-137 
21. De Jong S, Teerlink T. Analysis of 
asymmetric dimethylarginine in 
plasma by HPLC using a monolithic 
column. Anal Biochem 2006; 
353:287-289 
22. Teerlink T. HPLC analysis of ADMA and 
other methylated L-arginine analogs 
in biological fluids. J Chromatogr B 




Association of asymmetric 
dimethylarginine with sickle 
cell disease-related pulmonary 
hypertension 
Precious P. Landburg,1 Tom Teerlink,2 Eduard J. van 
Beers,3 Frits A.J. Muskiet,4 Mies C. Kappers-Klunne,5 
Joost W.J. van Esser,5 Melvin R. Mac Gillavry,6 Bart J. 
Biemond,3 Dees P.M. Brandjes,7 Ashley J. Duits1 and 
John-John Schnog1•5•7 
on behalf of the CU RAMA study groupt 
1 Immunology Laboratory Department, Red Cross Blood Bank 
Foundation Curai;:ao, Curai;:ao, Netherlands Antilles 2 Department of Cl inical Chemistry, VU Un iversity Medical 
Center, Amsterdam, the Netherlands 
3 Department of Hematology, Academic Medical Center, 
Amsterdam, the Netherlands 
4 Department of Pathology and Laboratory Medicine, 
University Hospital Groningen, Gron ingen, the Netherlands 
5 Department of Hematology, Erasmus Medical Center, 
Rotterdam, the Netherlands 
6 Department of Cardiology, Slotervaart Hospita l, Amsterdam, 
the Netherlands 
7 Department of I nternal Medicine, Slotervaart Hospital, 
Amsterdam, the Netherlands 
t The CU RAMA study group is a col laborative effort studying 
sickle cel l d isease in  the Netherlands Antilles and the 
Netherlands 
Haematologica 2008; 93:1410-1412 
90 
Asymmetric Dimethylarginine and Pulmonary Hypertension 
INTRODUCTION 
Pulmonary hypertension (PHT) occurs in approximately 30% of adult sickle cell patients 
and is associated with a high risk of early death. Hemolysis driven reductions in nitric 
oxide (NO) bioavailability resulting from NO scavenging by cell free hemoglobin and 
increased arginase activity are of importance in the pathophysiology of SCD-related 
PHT.1 
Elevated plasma concentrations of asymmetric dimethylarginine (ADMA) 
contribute to limiting NO bioavailability in SCD.2 ADMA and symmetric 
dimethylarginine (SDMA) derive from the irreversible post-translational methylation 
of arginine residues by protein arginine methyltransferases (PRMT) and are released 
as free amino acids upon proteolysis. ADMA (but not SDMA) competitively inhibits 
NO synthase (NOS) enzymes, thereby limiting NO production. ADMA is degraded by 
dimethylarginine dimethylaminohydrolases (DDAH) whereas SOMA is mainly cleared 
renally.3 Elevated plasma ADMA concentrations occur in several forms of PHT and 
are associated to PHT outcome.4•5 We investigated whether ADMA concentrations are 
associated with PHT in SCD. 
MATERIALS AND M ETHODS 
Serum and EDTA plasma samples were available from adult sickle cell patients 
consecutively screened for PHT with echocardiography as previously reported.6 
Mild and moderate-severe PHT are defined as tricuspid regurgitant jet flow velocity 
(TRV) of 2.5-2.9 m/s and TRV�3 m/s respectively, with pulmonary-artery pressures 
considered normal in patients with trace or no tricuspid regurgitation (with TRV 
assigned 1 .3 m/s). 1 Plasma concentrations of ADMA, SDMA, amino acids and 
serum soluble vascular cell adhesion molecule (sVCAM)-1 levels were determined 
as previously described.2-7 For analysis, HbSS and HbSf3°-thalassemia patients were 
grouped together, as were HbSf3+-thalassemia and HbSC patients. p-values <0.05 were 
considered statistically significant (SPSS 12.0.2, SPSS inc, Chicago, IL, USA). The study 
was carried out in accordance with the principles of the Declaration of Helsinki. 
Two out of 19 PHT patients had moderate-severe PHT. Hydroxyurea use did not 
differ between patients with and without PHT and no patients used anticoagulation, 
calcium antagonists, endothelin receptor blockers or sildenafil. Between-group 
comparisons were only performed in HbSS/HbS�0-thalassemia patients as only 3 
HbSC/HbS�+-thalassemia patients had PHT of whom one had blood samples drawn. 
RESULTS AND DISCUSSION 
ADMA concentrations in patients without PHT were high compared to previously 
reported values in healthy race-matched controls. Irrespective of PHT, HbSS/HbS�0-
thalassemia patients were characterized by lower hemoglobin, higher LDH, ADMA 
and sVCAM-1 concentrations than HbSC/HbSW-thalassemia patients (all p<0.001). 
ADMA and sVCAM-1 were higher in HbSS/HbSW-thalassemia patients with PHT than 
those without PHT, with a significant correlation between ADMA and TRV as well 
(Table 2). sVCAM-1 and hemoglobin were significantly correlated to TRV in HbSS/ 
HbS�0-thalassemia patients (r
5
=0.49, p=0.002, rs =-0.30, p=0.04, respectively). SDMA, 
but not ADMA, was significantly correlated to GFR (rs =-0.66, p<0.001, r
5 
=-0.08, 
p=0.60, respectively) in HbSS/HbSW-thalassemia patients. Given the relation between 
hemolysis and methylarginine concentrations, it is likely that the hemolytic rate is an 
important determinant of their production in SCD (likely due to the increased protein 
turn-over in the stress erythropoiesis), also explaining the higher concentrations in 
HbSS/HbSW-thalassemia patients. A relative decrease in renal function (generally 
more evident in HbSS/HbS�0-thalassemia patients) could contribute especially to 
SDMA elevations. Contributing factors related to the pulmonary vasculature could 
be shear stress induced PRMT activity8 and hypoxia induced DDAH downregulation.9 
Although difference in ADMA between patients with and without PHT seems modest, 
even small increases in extra-cellular ADMA lead to significant intra-cellular NOS 
inhibition through preferred cellular ADMA uptake over arginine.3 Indeed, plasma 
ADMA concentrations ?_0.64 µmol/L are associated with strongly reduced pulmonary 
artery endothelial NOS expression and early death in PHT patients.5 Based upon the 
strong correlation of sVCAM-1 to ADMA, it would be interesting to hypothesize that 
chronic hemolysis induced ADMA elevations significantly contribute to endothelial 
activation and dysfunction in SCD via NOS inhibition, and that patients with higher 
ADMA concentrations are more prone to develop a vasculopathy leading to 
complications such as PHT over time. 
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Arginase activity (reflected by arginine to ornithine ratios) is elevated in sickle cell 
patients with moderate-severe PHT but, in agreement with previous studies, 1•10 did 
not differ between patients with mostly mild PHT and those without PHT. Conceding 
the fact that we did not determine plasma arginase activity directly, these data suggest 
that ADMA could play a role of pathophysiological importance at a relatively earlier 
stage than arginase activity. 
The relatively small number of patients needs to be taken into account when 
interpreting these data and no conclusions can be drawn about HbSC/HbSj3+­
thalassemia patients. Also, right heart catheterization remains the gold standard 
diagnostic test for PHT and is recommended in sickle cell patients with moderate­
severe PHT detected with echocardiography. However, given the excellent correlation 
between pulmonary artery pressure and TRV in SCD,1 and the fact that an elevated 
TRV is the result of solely left-sided heart disease in only a minority of cases, 11 the 
lack of right heart catheterization is unlikely to have significantly affected our results. 
Lastly, our data are largely limited to patients with mild PHT. Nonetheless, mortality 
is high in these patients and plasma ADMA concentrations were well in the range 
associated with death in other forms of PHT.4•5 
Taken together, our data identify an association of plasma ADMA concentrations 
to PHT in SCD, possibly identifying a novel factor of importance in its pathophysiology. 
Also, ADMA induced limitation of NO production may well provide an important new 
mechanistic link between hemolysis and the characteristic endothelial activation of 
SCD. 
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Table 1 I Demographics and laboratory parameters in sickle cel l patients with and 
without pulmonary hypertension 
HbSS (n=40) / HbS�0-thalassemia (n=6) 
PHT - PHT + p 
N 28 18 
Age (years) 33 (21-44) 28 (22-52) 0.80 
Male:female 6:22 5 : 13 
TRV (m/s) 2.0 (1.3-2.3) 2.7 (2.6-2.8) 
PAP (mmHg) 21 (12-28) 34 (32-43) 
Hb (mmol/L) 5.7 (5.0-6.2) 4.9 (4.2-5.9) 0.05 
HbF (%) 10.6 (6.1-18.3) 5.9 (2.2-14.1) 0 .13 
LOH (U/L) 369 (300-515) 575 (388-846) 0.02 
GFR (ml/min) 151 (120-195) 120 (66-172) 0.10 
ADMA (µmol/L) 0.57 (0.52-0.65) 0.63 (0.58-0.79) 0.01 
SDMA (µmol/L) 0.47 (0.42-0.55) 0.51 (0.47-0.83) 0.07 
Arginine (µmol/L) 45 (32-56) 46 (41-62) 0.26 
Ornithine (µmol/L) 56 (42-66) 56 (45-75) 0.41 
Citrul l ine (µmol/L) 23 (16-32) 27 (20-32) 0.66 
Praline (µmol/L) 208 (162-257) 209 (176-234) 0.84 
Arginine/ornithine 0.84 (0.66-1.0) 0.93 (0.72-1.15) 0.45 
Arginine/citrul line 1.87 (1.66-2.49) 1.98 (1.43-2.65) 0 .84 
Arginine/praline 0.23 (0.18-0.31) 0.25 (0.19-0.35) 0.41 
sVCAM-1 (ng/ml) 1089 (801-1239) 1542 (1119-1880) 0.007 
Data are presented as medians with their corresponding interquarti le  ranges. A 
p-value <0.05 is considerd statistica l ly significant. *Right ventricular systolic pressure 
was estimated based on the modified Bernoul l i  equation (1)  and considerd to be equal  
to the systolic pulmonary artery pressure (sPAP) in absence of right ventricu lar outflow 
obstruction. ** Glomerular Filtration Rate (GFR) calculated with Cockcroft and Gault­
formula (males: creatin ine clearance = 1.23xweight x {140-age/seru m creatin ine, 
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ABSTRACT 
Asymmetric dimethylarginine (ADMA) is associated with pulmonary hypertension 
(PHT) in sickle cell disease (SCD). We studied the relationship of ADMA to other SCD­
related complications. Plasma ADMA and associated parameters were determined in 
52 HbSS/HbS�0-thalassemia and 24 HbSC/HbSW-thalassemia patients. As expected 
ADMA levels were higher in HbSS/HbS�0-thalassemia patients with PHT (p=0.018), 
but also in those with other hemolysis-associated complications such as leg ulcers 
(p=0.012), cholelithiasis (p=0.008) and priapism (p=0.02) compared with counterparts 
without these complications. ADMA levels did not differ between patients with and 
without other disease-related complications such as retinopathy and avascula r  
osteonecrosis. Higher ADMA concentrations therefore seem to  be  associated to the 
hemolytic phenotype of SCD. 
INTRODUCTION 
In sickle cell disease (SCD) reduced nitric oxide (NO) bioavailability leads to endothelial 
dysfunction and is associated with several vascular disease states, such as pulmonary 
hypertension (PHT), renal dysfunction, priapism, leg ulcers and stroke.1•2 Chronic 
hemolysis is considered the driving force behind the NO shortage characteristic of 
SCD.2•3 Circulating free hemoglobin released from red cel ls scavenges NO,4 while 
increased arginase activity secondary to chronic hemolysis also contributes by limiting 
arginine availability for NO synthesis.5 Hence, the more severe the hemolytic anemia, 
the greater the NO shortage. As such, two extremes within the SCD spectrum can be 
appreciated, i.e. patients with severe hemolysis characterized by a high incidence of 
PHT, priapism, leg ulcers and stroke (hemolytic phenotype), and those with low rates 
of hemolysis and high incidences of painful crises and acute chest syndrome (ACS) 
(vase-occlusive phenotype).6 
We previously reported that plasma asymmetric dimethylarginine (ADMA) 
concentrations are elevated in SCD.7 ADMA is an endogenous NO synthase (NOS) 
inhibitor that contributes to the chronic NO shortage in SCD. The ADMA levels are 
associated with the hemolytic rate, endothelial activation and with SCD-related PHT.7•8 
Moreover, plasma ADMA concentrations were recently identified as a risk factor for 
early death in SCD.9 However, whether ADMA is also related to other hemolysis­
related SCD complications is currently unknown. Therefore, we studied whether 
plasma ADMA concentrations are associated with hemolysis associated complications 
of SCD other than PHT in a well defined patient population. 
MATERIALS AND METHODS 
Patients 
This study was conducted between 2005 and 2007. Adult sickle cell patients cared 
for at the department of Internal Medicine of the Sint Elisabeth Hospital (Cura!;ao, 
Netherlands Antilles), the Slotervaart Hospital (Amsterdam, the Netherlands) and 
the department of Hematology of the Academic Medical Centre (Amsterdam, the 
Netherlands), were considered eligible. Blood samples were drawn from consecutively 
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obtained from all patients. This study was approved by the internal review board of 
the Academic Medical Centre and carried out in accordance with the principles of the 
Declaration of Helsinki of 1975, as revised in 2000. 
SCD-related manifestations 
In the outpatient clinics adult patients are regularly screened for SCD-related 
manifestations as previously defined and reported. 10 The following data were taken from 
the medical records: microalbuminuria: urinary albumin (mg/L) to urinary creatinine 
(mmol/L) ratio in mg/mmol >3.5 (males)/>2.5 (females) confirmed with the 24 hour 
urine collection with micro-albuminuria >30 mg/24 h. PHT: tricuspid regurgitation 
jet flow velocity (TRV) 2:2.5 m/s in rest detected by Doppler echocardiography. PHT 
was considered absent when no or only trace TRV is detected. Retinopathy: presence 
of at least mild non-proliferative retinopathy. Cholelithiasis: presence of gallstones 
(ultrasound) or previous cholecystectomy because of cholecystolithiasis. ACS: 
defined as previously described occurring between January 2002 and January 2007.11 
Symptomatic avascular osteonecrosis (AVN): local pain and reduced function with 
documented osteonecrosis of the femoral or humeral head (hip or shoulder X-ray) 
or a history of surgical intervention for osteonecrosis. Leg ulcers: chronic ulcers of 
the ankle not otherwise explained. Priapism: spontaneous painful erection requiring 
hospital care. Stroke: history of stroke confirmed by Magnetic Resonance Imaging 
or Computerized Tomography. Painful crises: the cumulative number of admissions 
for painful crises (defined as typical musculo-skeletal/abdominal pain not otherwise 
explained) from January 2002 until January 2007 was used to categorize patients into 
2 groups: 0-1 painful crisis per year and 2 or more painful crises per year. 
Laboratory determinations 
EDTA anti-coagulated plasma of 76 adult sickle cell patients was available to us.10 These 
were drawn between 2005 and 2007 and stored at -80 °C and never thawed before. 
100 Plasma concentrations of arginine, ADMA and symmetric dimethylarginine (SOMA) 
were measured by high-performance liquid chromatography with fluorescence 
detection as previously described, 12 with modified chromatographic separation 
conditions.13 The inter-assay and intra-assay coefficients of variation were <3% 
and <1.5% respectively for arginine, ADMA and SDMA. The upper limits (P97.5) of 
the reference range are 0.63 and 0.73 µmol/L for ADMA and SDMA, respectively.14 
Quantitative brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide 
(NTproBNP) levels were measured in EDTA plasma with a microparticle enzyme 
immunoassay (Abbott Diagnostics) and an electrochemiluminescence immunoassay 
(Roche Diagnostics), respectively. Serum soluble vascular cell adhesion molecule 
(sVCAM)-1 levels were determined according to the manufacturer's procedures (R&D 
Systems USA). Standard blood counts and clinical biochemistry (e.g. hemoglobin (Hb), 
leukocytes, creatinine and lactate dehydrogenase levels (LDH)) were determined 
according to local protocols. Glomerular filtration rate (GFR) was calculated with the 
Cockroft and Gault formula. 
Statistical analysis 
The most severe SCD genotypes (HbSS and HbSl3°-thalassemia) were grouped 
together, as were the relatively milder genotypes (HbSC and HbSj3+-thalassemia). 
Continuous data are presented as medians with their corresponding interquartile 
range {IQR) . Between-group statistical analysis were confined to comparisons where 
at least four cases were present per group, and organ damage had to be screened for 
in the two years prior to study inclusion. Between 2 groups differences were tested 
with the Mann-Whitney U test. For correlation studies the Spearman correlation 
coefficient (r) was calculated. p-values <0.05 were considered statistically significant 
(SPSS 12.0.2, SPSS inc, Chicago, IL). 
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RESULTS 
Patient characteristics and clinical data are shown in Table 1. Apart from retinopathy, 
cholelithiasis and a-thalassemia the frequency of other complications was too 
low in the HbSC/HbSW-thalassemia group to allow statistical analysis. There were 
no statistically significant differences in AOMA concentrations in the analyzed 
complications of the HbSC/HbSW-thalassemia group (Table 2} . In the HbSS/HbS�0-
thalassemia group the frequency of stroke was too low to allow statistical analysis. 
Plasma AOMA concentrations were significantly higher in patients with PHT and in 
patients with a history of cholelithiasis, leg ulcers and priapism. SOMA concentrations 
were significantly higher in patients with micro-albuminuria and PHT and lower in 
patients with a-thalassemia. Arginine and the arginine/AOMA ratio were significantly 
lower in patients with a history of ACS (Table 2}. AOMA and SOMA correlated inversely 
to Hb (r
5
=-O.47, p=O.OO1 and r
5
=-O.Sl, p=O.OO1 respectively} and positively to LOH 
(r
5
=O.54, p<O.OO1 and r
5
=Q.31, p=0.03 respectively}. SOMA, but not AOMA, was 




=-0.0B, p=0.60, respectively}. 
AOMA was positively correlated to BNP (r
5
=O.351, p=O.O11}. SOMA and sVCAM-1 
were both positively correlated to BNP (r
5
=O.458, p=O.OO1 and r
5
=0.573, p<O.OO1 
respectively} and NTproBNP (r
5
=0.475, p<O.OO1 and, r
5
=Q.538, p<O.OO1 respectively}. 
BNP was correlated to Hb (r
5
=-O.617, p<O.OO1}, LDH (r
5
=0.64, p<O.OO1} and GFR 
(r
5
=-O.318, p=O.O28}. NTproBNP was correlated to Hb (r
5
=-O.411, p=O.OO2), LOH 
(r
5
=0.38O, p=O.OO6} and GFR (r.=-O.39O, p=0.OO6}. 
Table 1 I Legenda 
Results are presented as medians with their corresponding IQR. 
ns = not significant 
GFR = Glomerular filtration rate; LOH = lactate dehydrogenase; sVCAM-1 = soluble 
vascular adhesion molecule-1; BNP = brain natriuretic peptide; NTproBNP = N-terminal 
pro-b-type natriuretic peptide; AOMA = asymmetric dimethylarginine; SOMA = 
102 symmetric dimethylarginine. 
• Fraction in percentages. 
b Cockcroft and Gault-formula (males: creatinine clearance = 1.23xweight x (14O-age/ 
serum creatinine, females: creatinine clearance = 1.O3xweight x (14O-age)/serum 
creatinine). 
Table 1 I Demographics and laboratory data of sickle cell patients 
HbSS/HbSW-thalassemia HbSC/Hbs�+-thalassemia 
(n = 52) (n = 24) p 
Age (years) 28 (21 -47) 30 (23-38) ns 
Male:female 14:38 13 :11 
Microalbuminuria• 17/42 (40.5) 1/22 (4.5) 
PHP 19/50 (38.0) 2/23 {8.7) 
Retinopathy• 12/44 (27.3) 14/24 (58.3) 
Cholelithiasis• 34/48 (70.8) 4/20 (20.0) 
ACS• 21/49 (42.9) 1/24 (4.2) 
AVN• 6/48 (12.5) 1/24 (4.2) 
Leg ulcers• 5/48 (10.4) 0/23 (O.O) 
Priapism• 5/14 (35.7) 0/11 {0.0) 
Stroke• 2/52 (3.8) 0/24 (0.0) 
Crises � 2/year• 7/49 {14.3) 2/24 (8.3) 
a-tha lassemia• 15/36 (41.7) 7/18 (38.9) 
GFR (ml/min)b 151 (113 - 182) 125 (114 - 139) ns 
LDH (U/L) 439 (330 -858) 232 (202 - 291) <0.001 
sVCAM-1 (ng/ml) 1122 (964 - 1357) 746 (622 - 971) <0.001 
BNP (pg/ml) 49 (26 - 106) 17 (22 - 44) <0.001 
NTproBNP (pg/ml) 101 (53 -158) 39 (22 - 44) <0.001 
ADMA (µmol/L) 0.60 (0.54 - 0.68) 0.49 (0.46 - 0.57) <0.001 
SDMA (µmol/L) 0.49 (0.42 - 0.58) 0.46 (0.44 - 0.56) ns 
Arginine (µmol/L) 56 (47-71) 68 (56 -79) ns 
Arginine/ADMA ratio 91 (72 - 115) 132 (113 - 165) 0.001 
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Table 2 I Parameters in the HbSS/HbSW-thalassemia patients with and  without SCD-
related complications 
without with p 
Microa/buminuria 
AOMA 0.59 (0.54-0.65) 0.58 (0.53-0. 71) ns 
Arginine 53.6 (46.6-70.9) 55 (46.2- 65.6) ns 
SOMA 0.46 (D.42-0.50) 0.56 (0.47-0.82) 0.021 
sVCAM-1 1072 (893.6-1257.2) 1165.6 (889.1-1342.6) ns 
PHT 
AOMA 0.57 (0.53-0.63) 0.61 (0.58-0.75) 0.018 
Arginine 51.4 (43.4-63. 7) 61.0 (48.6-71.1) ns 
SOMA 0.47 (0.41-0.53) 0.51 (0.46-0.83) 0.039 
sVCAM-1 1083.6 (807.7-1200.7) 1440.1 ( 1072.0-1877.8) 0.023 
Retinopathy 
AOMA 0.60 (0.56-0.68) 0.55 (0.51-0.73) ns 
Arginine 55.9 (46.8-69.8) 56.1 (49.4-68.9) ns 
SOMA 0.49 (0.44-0.57) 0.56 (0.44-0. 74) ns 
sVCAM-1 1144.5 (893.6-1451.5) 1114.6 (1072.0-1328.6) ns 
Cholelithiasis 
AOMA 0.56 (0.53-0.59) 0.63 (0.58-0.71) 0.008 
Arginine 55.3 (46.8-69.8) 54.2 (45.3-56.4) ns 
SOMA 0.48 (0.43-0.60) 0.49 (D.41-0.58) ns 
sVCAM-1 1049.0 (798.4-1285.0) 1164.2 (985.8-1546.4) ns 
ACS 
AOMA 0.60 (0.53-0.66) 0.58 (0.54-0.68) 0 ns 
Arginine 59.9 (53.5-71.2) 48.5 (38.6-59.5) 0.007 
SOMA a.so (0.43-0.57) 0.46 (0.43-0.66) ns 
104 sVCAM-1 1144.5 (989.9-1282.8) 1109.5 (727.2-1577.6) ns 
AVN 
AOMA 0.59 (0.54-0.68) 0.59 (0.53-0.62) ns 
Arginine 54.8 (46.6-66.9) 64.7 (56.3-84.7) ns 
Table 2 I Continued 
without with p 
SDMA a.so (0.44-0.58) 0.42 (0.40-0.50) ns 
sVCAM-1 1126.2 (985.8-1356.6) 1089.4 (711.4-1165.6) ns 
Leg u/cera 
ADMA 0.58 (0.53-0.65) 0.70 (0.68-0.82) 0.012 
Arginine 53.9 (46.0-71.0) 59.5 (56.7-61.0) ns 
SDMA 0.49 (0.43-0.56) 0.58 (0.50-0.84) ns 
sVCAM-1 1096.8 (814-1294.2) 1702.6 (1397.5-2374.8) 0.016 
Priapism 
ADMA 0.58 (0.53-0.65) 0.79 (0.63-0.86) 0.02 
Arginine 54.2 (47.0-65.8) 58.2 (41.6-71.2) ns 
SDMA 0.48 (0.42-0.58) 0.53 (0.46-0.84) ns 
sVCAM-1 1124.2 (814-1294.2) 1288.6 (1008.6-1877.8) ns 
�2 crises 
ADMA 0.59 (0.53-0.68) 0.63 (0.58-0.65) ns 
Arginine 56.0 (47.0-68.6} 51.4 (48.5-71.2) ns 
SDMA 0.50 (0.44-0.58) 0.41 (0.39-0.44) ns 
sVCAM-1 1120.4 (814-1356.6) 1162.8 (1126.1-1370.2) ns 
Alpha- thalassemia 
ADMA 0.63 (0.54-0.68) 0.58 (0.49-0.60) ns 
Arginine 61.0 (48.5-68.6) 54.4 (41.6-70.9) ns 
SDMA 0.55 (0.48-0.66) 0.45 (0.40-0.55) 0.02 
sVCAM-1 1238.6 (1053.6-1356.6) 1040.3 (746.7-1164.2) ns 
ns= not significant 
Data for stroke were not appl icable 
Data are presented as medians with their corresponding interquarti le range. 
Between group differences were tested with the Mann-Whitney U test 
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DISCUSSION 
The current study confirms the close associations of AOMA to the hemolytic phenotype 
of SCO, as plasma AOMA concentrations were significantly higher in patients 
with several hemolysis-associated complications next to PHT such as leg ulcers, 
priapism and cholelithiasis. AOMA concentrations were, however, not associated to 
complications of the vase-occlusive phenotype such as painful crises and ACS. The 
latter is in accordance with our recent finding that plasma AOMA concentrations 
do not increase further during painful crises.15 Plasma AOMA levels were lower in 
patients with a-thalassemia, even though this did not reach statistical significance. 
Serum LOH levels were higher only in patients with PHT and microalbuminuria (LOH 
levels would have been expected to be higher in patients with hemolysis associated 
complications). The relatively low number of patients is the likely explanation for 
these findings, as both a-thalassemia and LOH are related to hemolysis associated 
complications in several larger studies.16•17 The lack of statistically significant relations 
of arginine/AOMA to hemolysis associated complications may be the result of both 
the greater variation of ratio's as compared to AOMA and the relatively small patient 
sample. However, it is unknown at present whether AOMA concentrations or arginine/ 
AOMA ratio's are better predictors of NOS inhibition. 
NTproBN P  and BNP are natriuretic hormones mainly released into the blood due 
to cardiomyocyte stretch. Their serum levels reflect the extent of cardiac chamber 
volume and pressure overload.18 Both are accepted as diagnostic and prognostic 
markers for patients with PHT, 19 and several studies have suggested serum (pro) 
BNP levels to indicate the presence of PHT in SC0.20•21 It is well established that the 
major factor determining the development of left ventricular hypertrophy in SCO is 
the degree of anemia which, before onset of renal dysfunction, is mainly determined 
by hemolytic rate.22 In this light we recently reported hemoglobin levels and renal 
function to be the most important determinants of (NTpro)BNP levels in SCO, and 
not the presence of (mild) PHT.23 The stronger association of (NTpro)BNP to SOMA 
than to AOMA, with the former being completely renally cleared, further supports the 
concept that in SCO renal function is a major determinant of (NTpro)BNP levels. Given 
the fact that PHT and renal dysfunction often coincide in SCD,24,25 caution is advised 
when using (NTpro)BNP as a marker for PHT in SCD. 
A limitation of this study is the small number of patients. Consequently, 
several complications (e.g. stroke in the HbSS/HbSW-thalassemia group and all but 
retinopathy, cholelithiasis and a-thalassemia in the HbSC/HbSW-thalassemia group) 
did not occur at a sufficient rate to allow statistical analysis. The present data should 
therefore be interpreted with caution and need reconfirmation in a larger cohort. 
Taken together, our data shows for the first time, an association of plasma ADMA 
concentrations to hemolysis-related complications in SCD other than PHT thereby 
supporting the important role of ADMA in the pathophysiology of the SCD hemolytic 
phenotype. 
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SUM MA RY AND CONCLUS ION 
Sickle cell disease (SCD) is one of the most common hereditary disorders in the world 
affecting millions of people. SCD is particularly common among those whose ancestors 
come from Sub-Saharan Africa, Saudi Arabia, India, and Mediterranean countries. The 
mutation GAG➔GTG substitutes valine for glutamic acid at position 6 in the �-globin, 
gene resulting in the �5-globin gene. The underlying cause of SCD is the inheritance 
of two copies of the mutant W-globin gene (leading to sickle cell anemia, or the HbSS 
genotype), or one W-globin gene in combination with other abnormal hemoglobin 
such as HbC or with �-thallasemic genes. 
HbS polymerizes upon deoxygenation. The polymers make the erythrocyte 
rigid, distort its shape, and cause structural damage in the red-cell membrane, 
all of which alter the rheologic properties of the cell, impair blood flow through 
the microvasculature, and lead to both hemolysis and vaso-occlusive episodes. 
The extent of HbS polymerization is proportional to the degree and duration of 
hemoglobin deoxygenation and intracellular HbS concentration. Fetal hemoglobin in 
the erythrocyte reduces the concentration of HbS and also reduces its polymerization. 
SCD is heterogeneous in its presentation, with differences in the rate and severity 
of complications even within a single genotype. Even patients with the most severe 
genotype, HbSS, may vary in their clinical presentation from being continuously 
admitted for the management of acute complications to rarely requiring medical care. 
The complications of SCD are myriad, but the most common is the vaso-occlusive 
painful crisis. With increasing age and improved supportive care chronic end-organ 
complications are becoming an increasing chal lenge for the treating clinician. 
The care of patients with SCD has undergone important advances in recent years, 
with screening programs in many countries leading to timely institution of vaccinations 
and penicillin prophylaxis as well as the discovery of hydroxycarbamide (also known 
as hydroxyurea) as an efficacious drug for managing patients with SCD. New drugs 
are currently being examined. Concepts of individualized pain relief strategies and 
combination therapy have been further explored in more recent years, also offering 
promise to improve the care of patients with SCD. The improved supportive care has 
increased life expectancy of SCD patients in Western countries into the fourth and 
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fifth decade of life.1 Nonetheless; increased understanding of the pathophysiology in 
SCD is needed in order to expand treatment options. 
The first chapter of this thesis gives an outline of SCD clinical outcome, 
pathophysiology and treatment options. As long as the pathophysiology is not 
completely understood it will be difficult to find effective treatments or treatment 
strategies. The studies presented in this thesis focus on the potential roles of 
angiogenesis and NO bioavailability in the pathophysiology of SCD. 
Angiogenesis is a well orchestrated process determined by the relative levels of 
pro-and anti-angiogenic factors involving endothelial cell activation.2 Angiogenesis 
is thought to play an important role in the pathophysiology of SCD and SCD-related 
complications. The formation of abnormal blood vessels and the process of vascular 
remodeling likely contribute significantly to SCD-related morbidity.3 SCD patients have 
been demonstrated to be in a pro-angiogenic state due to increased angiopoietin-2 
levels in relation to angiopoietin-1 and vascular endothelial growth factor (VEGF).4 
In chapter two we describe the contribution of anti-angiogenic factors to this pro­
angiogenic state in clinically asymptomatic sickle cell patients. SCD is characterized by 
elevated blood levels of pro-inflammatory cytokines and tissue hypoxia which are both 
known to increase VEGF and placenta-like growth factor (PIGF) levels.5 Nevertheless 
compared to healthy controls no increment of VEGF and PIGF is seen during steady 
state in SCD which could be related to increased levels of anti-angiogenic factors. 
Soluble Fms-like tyrosine kinase (sFlt)-1 and soluble endoglin (sEng) are known to 
sequester and inhibit VEGF, PIGF and transforming growth factor-�1 signaling hence 
neutralizing their pro-angiogenic response. Compared to healthy controls we found 
increased sFlt-1 and sEng levels during steady state in our SCD population which are 
thought to sequester circulating free VEGF/PIGF resulting in unaltered VEGF/PIGF 
levels. 
Endothelial cell activation and dysfunction due to decreased NO bioavailability 
contribute to angiogenic growth factor release resulting in an impaired ability to 
mount an adequate angiogenic response which is thought to be implicated in the 
development of PHT.6-9 SCD is characterized by continuous endothelial cell activation, 
ongoing (low grade) tissue ischemia and continuously elevated erythropoietin 
levels due to the hemolytic anemia, all factors known to induce or contribute to 
angiogenesis. In several complications that occur in SCD, such as PHT, retinopathy, 
Moyamoya syndrome and stroke, angiogenesis has proven its role of importance.3•4•10 
Although angiogenic growth factor levels have been shown to differ from healthy 
controls we did not find a relation between the altered levels and SCD-related 
complications as shown in chapter three. This does not rule out a role of importance 
in the development of SCD-related complications since only few angiogenic factors 
are known which have only recently been studied. This outcome only emphasizes the 
complexity of the angiogenic response and SCD pathophysiology. 
Tissue ischemia is probably one of the leading factors to a pro-angiogenic state 
that is likely to be involved in reendothelialization and neovascularization.4 After 
acute tissue ischemia and endothelial damage, as seen during SCD painful crises, 
circulating endothelial cells (CECs) are mobilized in order to take part in endothelial 
neovascularization. CECs are indicative of vascular and endothelial injury.11 In the 
study described in chapter four we measured CECs and report a possible relation of 
in vivo CECs to SCD-related organ damage since CEC levels appeared to be highest in 
those with extensive organ damage.12 
Tissue damage and hypoxia are both known to up-regulate many angiogenic 
factors and cytokines such as stromal-derived factor (SDF}-1 and its receptor CXCR4 
(CD184) which both have been recognized as key mediators of angiogenesis and 
inflammation.13·14 SDF-1 has also been demonstrated to be involved in the recruitment 
of CECs in order to support the revascularization process after endothelial damage 
and during hypoxia. lschemia-reperfusion injury, hemolysis resulting in reduced nitric 
oxide (NO) and hypoxia are characteristic for SCD therefore we studied the role of 
SDF-1 in SCD and SCD-related complications in chapter five. No increment of SDF-1 
was seen during an uncomplicated painful crisis. However, significant higher levels of 
SDF-1 have been found in patients with SCD-related pulmonary hypertension (PHT), 
suggesting a potential role of SDF-1 in SCD-related PHT pathophysiology. 
The second part of this thesis focused on the role of the reduced NO bioavailability 
in the pathophysiology in SCD. NO plays a central role in vascular homeostasis 
and during the clinically asymptomatic state NO bioavailability is reduced in SCD. 
Asymmetric dimethylarginine (ADMA) is an endogenous NO synthase inhibitor that 
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contributes to the chronic NO shortage in SCD. In chapter six we demonstrate that 
during asymptomatic state ADMA concentrations are elevated and do not show 
further increment during painful crises. Decreased NO bioavailability due to increased 
arginase activity and intravascular hemolysis are thought to play a substantial role 
in the development of SCD-related PHT.15-17 In chapter seven we show increased 
ADMA concentration in SCD-related PHT, therefore identifying a possible contributory 
mechanism leading to reduced NO bioavailability in relation to SCD-related PHT. 
Chronic hemolysis is considered the driving force behind the NO shortage in SCD. 17•18 
Two extremes within the SCD spectrum can be appreciated, i.e. patients with severe 
hemolysis, PHT, leg ulcers, priapism and stroke, which some refer to as the hemolytic 
phenotype and those with low rates of hemolysis, high incidence of painful crises and 
acute chest syndrome, which some refer to as the vase-occlusive phenotype. Indeed, 
as demonstrated in chapter eight, ADMA concentrations were significantly higher in 
patients with higher hemolytic rates. 
FUTURE PE RS PECTIVES 
SCD is a complex and debilitating disease. Since there are little therapeutic options 
rapid understanding of the pathophysiology is merited also to prevent development 
of SCD-related complications. Accurate objective laboratory parameters that reflect 
the in vivo rate of developing organ damage in SCD are needed since laboratory 
markers such as lactate dehydrogenase, leukocyte count and fetal hemoglobin 
percentage are not sufficiently reliable in predicting developing organ damage in the 
individual patient.19 In order to monitor in vivo endothelial damage in SCD endothelial 
cell specific and easily measurable markers are necessary. In SCD biomarkers are 
thought to play an important role in disease management and many different markers 
in blood and urine have been described. Nevertheless their value herein is unclear 
since only few biomarkers relate clearly or causally to pathological processes.20 
Finding suitable biomarkers would facilitate early diagnosis of complications, early 
detection of (chronic) organ damage and might also be useful in monitoring response 
to treatment. Biomarkers might even be able to point out high-risk patients in 
SCD. Due to the complex pathophysiology finding such a marker within the known 
118 angiogenic factors is challenging. Anti-angiogenic factors play a role in maintaining the 
pro-angiogenic state yet their role in the development of SCD-related complications 
is still to be elucidated. One might hypothesize that during the development of SCD­
related complications the levels of anti-angiogenic factors substantially increase in 
an attempt of the body to counteract angiogenesis as is seen in pre-eclampsia.21•22 
Prospective studies are necessary in which patients are enrolled from birth. Frequent 
blood sampling, detailed monthly history and yearly screening for SCD-related 
complications might provide angiogenic risk profiles enabling early detection of 
developing complications. 
We have shown that CECs might be associated to SCD-related organ damage. 
Further study should address the factors that are of importance for the mobilization 
of CECs in SCD as this may reveal potential markers of disease severity. 
Recently Parent et al have shown by right heart catheterization that the estimated 
prevalence of SCD-related PHT seems to be 6% instead of 30% as measured by 
echocardiography.23 Nevertheless they and earlier studies have shown that the 
mortality rate still remains high in SCD patients with TRV �2.5 m/sec. Even more, 
autopsy studies show signs of PHT in 30% of SCD patients.24 Given the provocative 
data recently published by Parent et al angiogenic factors should also be studied in 
SCD patients with PHT confirmed by right heart catheterization.23 Since ADMA seems 
to be associated to several nonhemolytic driven forms of PHT and is associated 
with SCD-related PHT it would be interesting to correlate findings with right heart 
catheterization to ADMA concentrations.25 
With further regard to ADMA a recent study showed in vitro and in vivo that 
in atherosclerotic disease the use of flavonol quercetin, a product that is found in 
red wine and tea, decreased the systemic ADMA levels.26 In a healthy population 
an increase of NO bioavailability was shown in response to flavonol quercetin.27 
Therefore, the potential effect of flavonol quercetin on ADMA concentrations should 
also be studied in SCD patients. 
As of yet allogeneic stem cell transplantation is the only curative treatment in SCD. 
Patients eligible for bone marrow transplant are those with severe disease defined 
by history of stroke, >3 severe vase-occlusive crises per year, osteonecrosis and red 
blood cell alloimmunization. Studies have shown a 94% probability of survival and an 
84% event free survival.28•29 Nevertheless due to lack of suitable matched donors and 
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the chronic use of immunosuppressive drugs with serious side effects the treatment 
is rarely used. Moreover, most sickle cell patients live in countries where stem cell 
transplantations are not readily available. Studies on curative treatment are scarce 
in SCD yet recently a very promising study has been published showing that silencing 
of BCLllA, which is a repressor of y-globin expression, in an animal study induced 
high level fetal hemoglobin induction correcting the hematologic and pathologic 
defects associated in SCD.30 Although with this study a potential for an effective or 
even 'curative' treatment may be found, this is not likely to benefit most patients. In 
order to keep developing novel widely applicable therapeutics the search to markers 
that define the pathophysiology in SCD remains of importance in order to enable risk 
assessment and to optimize therapeutic regiment. 
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SAMENVATTING EN CONCLUSIE 
Sikkelcelziekte (SCZ) is wereldwijd een van de meest voorkomende erfelijke 
aandoeningen. Oorspronkelijk werd de ziekte gezien in Afrika, Saudi-Arabie, India 
en mediterraan gelegen landen echter door slavernij en migratie komt de ziekte nu 
wereldwijd voor. SCZ wordt veroorzaakt door een puntmutatie op positie 6 in het 
�-globine gen waardoor valine vervangen wordt door glutaminezuur resulterend 
in het �5-globine gen, HbS. De onderliggende oorzaak van SCZ is de overerving van 
twee kopieen van het mutante �5-globine gen (wat leidt tot sikkelcelanemie, of het 
HbSS genotype), of een �5-globine gen in combinatie met een andere abnormale 
hemoglobine zoals HbC of �-thallasemie. 
Door de mutatie in sikkelcellen vormt de hemoglobine bij deoxygenatie lange 
ketens van polymeren. De polymeren maken erytrocyten rigide, waarna zij tot 
vervorming en structurele schade leiden aan de rode bloedcelwand. Dit a l ies verandert 
de rheologische eigenschappen van de eel, dat resulteert in een bemoeilijkte 
bloeddoorstroming door de microvascularisatie, hemolyse en vaso-occlusieve 
episodes. De mate van HbS polymerisatie wordt be"invloed door hemoglobine 
deoxygenatie als oak de intracellulaire HbS en foetaal hemoglobine concentratie. 
Binnen een genotype worden er verschillen in de mate en ernst van complicaties 
gezien. Zelfs de presentatie van patienten met het ergste genotype, HbSS, kunnen 
varieren van frequente opnames voor behandeling van acute complicaties tot zelden 
een noodzaak voor medische interventie. Er zijn veel complicaties beschreven van 
SCZ maar de meest voorkomende is de vaso-occlusieve pijncrise. Naar mate patienten 
ouder warden en er steeds betere ondersteunende behandelingen zijn warden 
chronische orgaancomplicaties een grotere uitdaging voor de behandelaar. 
De zorg van patienten met SCZ is de afgelopen jaren sterk verbeterd door 
screeningsprogramma's wat in veel landen leidt tot tijdige vaccinering en penicilline 
profylaxe. Oak de ontdekking van hydroxycarbamide (beter bekend als hydroxyurea) 
is een effectief/doeltreffend middel voor de behandeling van SCZ. Concepten van 
individuele pijnbestrijdingstrategieen en combinatietherapie lijken veelbelovende 
therapieen te zijn die de laatste jaren warden onderzocht ter verbetering van de 
zorg voor SCZ. De levensverwachting van patienten met SCZ in Westerse landen is 
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door verbeterde medische zorg gestegen naar een gemiddelde levensverwachting 
van veertig a vijftig jaar.1 Echter, aangezien in de Westerse landen de gemiddelde 
levensverwachting rand de tachtig jaar ligt is beter begrip van de pathofysiologie in 
SCZ nodig om de behandelopties te vergroten en de levensverwachting nog verder op 
te trekken richting die van de gemiddelde populatie. 
Het eerste hoofdstuk van dit proefschrift geeft een overzicht van de klinische 
uitkomsten, pathofysiologie en huidige behandelopties. De overige hoofdstukken in 
dit proefschrift richten zich op de potentiele rol van angiogenese en de biologische 
beschikbaarheid van nitriet oxide (NO) in de pathofysiologie van SCZ. 
Angiogenese is een goed georganiseerd proces dat be"invloed wordt door de 
relatieve waarden van de pro-en anti-angiogene factoren.2 Van angiogenese wordt 
gedacht dat het een belangrijke rol speelt in de pathofysiologie van SCZ en aan SCZ­
gerelateerde complicaties. De vorming van abnormale bloedvaten en het proces van 
vasculaire remodellering dragen waarschijnlijk significant bij aan de morbiditeit.3 
In de studie van Duits et al wordt aangetoond dat patienten met SCZ in een pro­
angiogene staat zijn wat ten gevolge van gestegen angiopoietine-2 waarden in relatie 
tot angiopoietine-1 en vascular endothelial growth factor (VEGF) waarden is.4 In 
hoofdstuk twee beschrijven we de bijdrage van anti-angiogene factoren aan de in 
standhouding van de pro-angiogene staat bij klinisch asymptomatische SCZ patienten. 
Verhoogde waarden van pro-inflammatoire cytokinen en weefsel hypoxie dragen bij 
aan een stijging van VEGF en placenta-like growth factor (PIGF) waarden.5 Desondanks 
wordt er, vergeleken met gezonde mensen, geen stijging van VEGF en PIGF gezien 
tijdens de asymptomatische staat in SCZ wat een gevolg l ijkt te zijn van gestegen 
anti-angiogene factor waarden. Soluble Fms-like tyrosine kinase (sFlt)-1 en soluble 
endoglin (sEng) sekwestreren en inhiberen signalen van VEGF, P IGF en transforming 
growth factor-131, daarmee de pro-angiogene respons neutraliserend. Vergeleken met 
gezonden werden verhoogde sFlt-1 en sEng waarden gemeten in de asymptomatische 
sikkelcel populatie. De onveranderde VEGF/PIGF waarden ontstaat doordat sFlt-1 en 
sEng vrij VEGF/PIGF wegvangen. 
Endotheliale eel activiteit en disfunctie ten gevolge van verminderde NO 
biobeschikbaarheid dragen bij aan het vrijkomen van angiogene groei factoren. 
Dit resulteert in een veranderd vermogen om een adequate angiogene respons te 
bewerkstelligen die van belang geacht wordt bij de vorming cq het ontstaan van 
pulmonale hypertensie ( PHT).6-9 SCZ wordt verder ook gekarakteriseerd door factoren 
die angiogenese induceren of hieraan bijdragen zoals continue endothel iale activatie, 
continue (laaggradige} weefsel ischemie en continue geeleveerde erytropoietine 
waarden ten gevolge de hemolyse. In sommige complicaties die bij SCZ voorkomen, 
zoals PHT, retinopathie, Moyamoya syndroom en beroerte is de rol van angiogenese 
beschreven.3•4•10 Alhoewel in SCZ angiogene groeifactor waarden blijken te verschillen 
van gezonde mensen wordt in hoofdstuk zes geen relatie gevonden tussen veranderde 
angiogene groeifactor waarden en SCZ-gerelateerde complicaties. Dit sluit een rol 
voor angiogene factoren in de ontwikkeling van SCZ-gerelateerde complicaties niet 
uit aangezien slechts enkele angiogene factoren bekend zijn en zij pas sinds kort 
onderzocht worden. Deze uitkomst benadrukt juist de complexiteit van de angiogene 
respons en pathofysiologie van SCZ. 
Weefsel ischemie is waarschijnlijk een van de voornaamste factoren in 
de pro-angiogene staat die betrokken lijkt te zijn bij de reendothelialisatie en 
neovascularisatie.4 Na acute weefsel ischemie en endotheliale schade, zoals gezien 
wordt tijdens SCZ pijncrisen, worden circulerende endotheliale cellen (CECs} 
gemobiliseerd om deel te nemen aan de endotheliale neovascularisatie. CECs zijn 
indicatief voor vasculaire en endotheliale schade.11 In hoofdstuk drie warden de CEC 
waarden gemeten.12 Zij geven een mogelijke relatie weer van in vivo CECs ten aanzien 
van SCZ-gerelateerde orgaanschade daar CEC waarden het hoogst zijn bij die genen 
die de ergste vorm van orgaanschade vertonen. 
Weefselschade en hypoxie staan er bekend om angiogene factoren en cytokinen 
op te reguleren zoals stromal-derived factor (SDF}-1 en zijn receptor CXCR4 (CD184}. 
SDF-1 en zijn receptor worden op hun beurt gezien als belangrijke mediatoren van 
angiogenese en inflammatie.13·14 Van SDF-1 is ook aangetoond dat zij betrokken 
is bij het aantrekken van CECs om het revascularisatie proces te ondersteunen na 
endotheliale schade en tijdens weefsel hypoxie. lschemie-reperfusie schade, hypoxie 
en hemolyse resulterend in verlaagde NO biobeschikbaarheid zijn karakteristiek voor 
SCZ. In hoofdstuk vijf wordt de rol van SDF-1 in SCZ en SCZ-gerelateerde complicaties 
beschreven. Er werd geen toename van SDF-1 gezien tijdens ongecompliceerde 
pijncrise. Significant hogere waarden van SDF-1 zijn gezien in patienten met 
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SCZ-gerelateerde PHT, wat kan duiden op een potentiele rol voor SDF-1 in de 
pathofysiologie van SCZ-gerelateerde PHT. 
Het tweede deel van dit proefschrift richt zich op de rol van de NO 
biobeschikbaarheid in de pathofysiologie van SCZ. NO speelt een centrale rol in 
de vasculaire homeostase en tijdens de klinische asymptomatische staat is NO 
biobeschikbaarheid gereduceerd. Asymmetrische dimethylarginine (ADMA) is 
een endogene NO synthase inhibitor die bijdraagt aan het chronische NO tekort in 
SCZ. In hoofdstuk zeven wordt aangetoond dat tijdens de asymptomatische staat 
ADMA concentraties verhoogd zijn; deze waarden stijgen echter niet verder tijdens 
een pijncrise. Van verlaagde NO biobeschikbaarheid ten gevolge van toegenomen 
arginase activiteit en intravasculaire hemolyse wordt gedacht dat zij een substantiele 
rol spelen in de ontwikkeling van SCZ-gerelateerde PHT.15-17 In hoofdstuk acht 
worden de gestegen ADMA concentraties in SCZ-gerelateerde PHT getoond, 
hiermee een mogelijke bijdragend mechanisme identificerend tot gereduceerde 
NO biobeschikbaarheid in relatie tot SCZ-gerelateerde PHT. Chronische hemolyse 
wordt gezien als de drijvende kracht achter het NO tekort in SCZ.17•18 Binnen het SCZ 
spectrum worden twee extremen gezien. Dit zijn patienten met ernstige hemolyse, 
PHT, beenulcera, priapisme en beroerten wat door sommigen omschreven wordt 
als het hemolytische fenotype versus die genen met lage mate van hemolyse, hoge 
incidentie van pijncrise en acuut chest syndroom wat door sommigen gezien wordt 
als het vaso-occlusieve fenotype. Zeals aangetoond in hoofdstuk negen zijn de ADMA 
waarden significant hoger in patienten met hogere hemolytische waarden. 
TOE KO MST PE RSPECTIEVEN 
SCZ is een complexe ziekte met een hoog morbiditeitgehalte. Aangezien er weinig 
therapeutische opties zijn is snel begrip van de pathofysiologie noodzakelijk om de 
ontwikkeling van SCZ-gerelateerde complicatie te voorkomen. Accurate objectieve 
laboratorium parameters die in vivo de mate van ontwikkeling van orgaanschade in SCZ 
reflecteren zijn nodig aangezien biomarkers zeals lactaat dehydrogenase, leukocyten 
aantal en het foetale hemoglobine percentage onvoldoende betrouwbaar zijn in het 
voorspellen van de ontwikkeling van orgaanschade in de individuele patient.19 Om 
128 de in vivo endotheliale schade te monitoren in SCZ zijn endotheliale eel specifieke en 
makkelijk te meten markers nodig. In SCZ wordt een belangrijke rol toegeschreven 
aan biomarkers voor ziekte management. Zowel in bloed als urine zijn markers 
beschreven, desondanks is hun waarde onduidelijk aangezien er van slechts enkele 
biomarkers een duidelijk causaal verband met pathologische processen gevonden 
is .20 Het vinden van geschikte biomarkers zou vroege detectie van (chronische) 
orgaanschade vergemakkelijken wat ook van waarde is tijdens het monitoren van 
respons op behandel ing . Biomarkers zouden zelfs in staat kunnen zijn om hoogrisico 
patienten aan te tonen in SCZ . Ten gevolge van de complexe pathofysiologie is het 
vinden van zo een marker een grote uitdaging. Anti-angiogene factoren spelen een 
rol in het handhaven van de pro-angiogene staat echter de rol in de ontwikke ling van 
SCZ-gerelateerde complicaties dient nog aangetoond te warden . Hypothetisch gezien 
zou het zo kunnen zijn dat tijdens de ontwikkeling van SCZ-gerelateerde complicaties 
de waarden van anti-angiogene factoren substantieel stijgt in een paging van het 
lichaam om angiogenese tegen te werken zoals gezien wordt bij pre-eclampsie. 21•22 
Prospectieve studies zijn nodig waarbij patienten vanaf de geboorte ge"includeerd 
warden . Frequente bloedafnames, gedetailleerde maandelijkse anamnese en 
jaarl ijkse screening voor SCZ-gerelateerde complicaties kunnen wellicht angiogene 
profielen tentoonspreiden die vroege detectie van ontwikkeling van complicaties kan 
bewerkstelligen. 
In dit proefschrift wordt een mogelijke associatie aangetoond tussen CECs en SCZ­
gerelateerde orgaanschade. Verdere onderzoeken zijn nodig naar de factoren die van 
belang zijn voor de mobilisatie van de CECs in SCZ aangezien zij potentiele biomarkers 
voor ziekte ernst zouden kunnen ontwaren . 
Recent heeft Parent et al aangetoond door middel van rechtszijdige 
hartkatheterisatie de geschatte prevalentie van SCZ-gerelateerde PHT 6% blijkt te zijn 
in plaats van 30% die aangetoond wordt door echocardiografie. Desondanks tonen zij 
en anderen een hoge mortaliteit aan in sikkelcel patienten met tricuspide regurgitatie 
jet flow van ?_2 .5 m/sec . Daarnaast tonen autopsie studies in 30% van de sikkelcel 
patienten aanwijzingen voor PHT.24 Gezien de provocerende data gepubliceerd door 
Parent et al zouden angiogene factoren ook bestudeerd moeten worden in SCZ 
patienten met PHT aangetoond met rechtszijdige hartkatheterisatie. Aangezien ADMA 
geassocieerd is met verschillende vormen van PHT die niet door hemolyse gedreven 
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warden en is geassocieerd met SCZ-gerelateerde PHT is het interessant om de 
uitkomsten te correleren aan rechtszijdige hartkatheterisatie en ADMA concentraties. 
Ten aanzien van ADMA heeft recent onderzoek in vitro en in vivo aangetoond dat 
bij atherosclerose gerelateerde ziekten flavonol quercetin, een product dat gevonden 
wordt in rode wijn en thee, de systemische ADMA concentratie reduceert.26 In een 
gezonde populatie werd een toename van de NO biobeschikbaarheid gezien in 
respons op het f lavonol quercetin. Daarom dient het potentiele effect van flavonol 
quercetin op ADMA concentraties oak in de sikkelcel populatie bestudeerd te warden. 
Allogene stamceltransplantatie is de enige curatieve behandeling voor SCZ. 
Patienten kunnen in aanmerking komen voor een beenmergtransplantatie als zij een 
ernstige ziektevorm hebben welke gedefinieerd wordt door een voorgeschiedenis 
met waarin beroerte, �3 ernstige vaso-occlusieve crisen per jaar, osteonecrose 
en rode bloedcel alloimmunizatie. Studies hebben aangetoond dat er een 94% 
overlevingskans bestaat en 84% kans op een complicatie vrije overleving.28•29 Door het 
tekort aan geschikte donoren en het chronische gebruik van immunosuppressiva met 
ernstige bijwerkingen wordt de behandeling zelden gebruikt. Verder leven de meeste 
sikkelcel patienten in landen waar de stamceltransplantatie niet gemakkelijk voor 
handen is. Onderzoeken naar curatieve behandeling zijn zeldzaam binnen SCZ echter 
recent is er een veelbelovende studie gepubliceerd die gebruik maakt van silencing 
van BCLllA. BCLllA onderdrukt de y-globine expressie, in een dierenstudie wordt 
een hoge concentratie foetaal hemoglobine ge'induceerd wat de hematologische 
en pathologische defecten in SCZ lijkt te corrigeren.30 Hoewel met deze studie een 
potentieel effectieve of zelfs "curatieve" behandeling gevonden lijkt te zijn, zullen niet 
veel patienten hier profijt van hebben aangezien het merendeel van de patienten 
in de zogenaamde 3de wereldlanden woonachtig is. Om wereldwijd toepasbare 
therapieen te ontwikkelen is de zoektocht naar markers die de pathofysiologie van 
SCZ definieren van belang ten faveure van risicostratificatie en optimalisatie van 
therapeutische regimenten. 
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Dit proefschrift zou er nooit zijn geweest zonder inzet en steun van velen! Als u 
dit proefschrift ontvangen heeft behoort u tot de groep mensen naar wie deze 
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In dit dankwoord wil ik een aantal mensen hier in het bijzonder danken. 
Allereerst gaat mijn dank uit naar alle patienten en vrijwilligers die met een 
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hebben genomen. 
Mijn promoter en co-promoter, prof. dr. Ashley Duits en dr. John-John Schnog, 
masha masha danki pa guiami den e mundo aki. Danki pa e fe y e yudansa (ku mi ta tin 
mester sigur !) pero tambe mi ta apresia e koperashon di boso. Het was een leerzame 
wetenschappelijke tocht, een vruchtbare en interessante latrelatie. 
De commissieleden, prof. dr. M.M. Levi, prof. dr. B. Lowenberg en prof. dr. R.0.8. 
Gans wil ik hier graag bedanken voor de beoordeling van het proefschrift en de 
bereidheid om zitting te nemen in mijn promotie commissie. 
Dank ook aan Elcida, Erwin, Furgel, Gilda, Luigi, Maida, Melissa, Phary, Ruigino, 
Ruthsella, Sharine, Sharline en Sysline van Stichting Rode Kruis Bloedbank Curai;ao. 
Vele uren heb ik in volle concentratie samen met jullie in de bloedbank doorgebracht. 
De humor en gezelligheid waarmee mijn verblijf bij jullie gepaard ging was ongekend. 
lk denk nog vaak genoeg aan onze lunch onderbrekingen ... Masha danki. 
Dank aan alle medewerkers van het Sint Elisabeth Hospitaal en vooral die van de 
SEH. Zonder jullie had ik de taal niet zo snel geleerd en dankzij jullie toewijding heb ik 
zoveel patienten kunnen includeren. Daarnaast gaven jullie mij de ruimte om mij als 
jonge dokter te ontpoppen. 
Speciale dank aan alle artsen van het Sint Elisabeth Hospitaal (SEHOS) in het 
bijzonder Nouaf Ajubi, Ken Berend, Monique Calmes, Sandra Cova, Jeanne Koeijers 
en Jeroen Romer die altijd in mij geloofd hebben en waar ik zelfs na mijn vertrek van 




Dank aan alle artsen, arts-assistenten en medewerkers van het 
Slotervaartziekenhuis, OLVG en AMC. Dees Brandjes en Jan-Willem Mulder dank voor 
de kans en mogelijkheid om mij na mijn vertrek van Cura�ao als clinicus verder bij 
jullie te mogen ontwikkelen. Yves Smets en Jos Frissen, slechts een jaar zat ik in het 
OLVG maar die periode was in alle opzichten onvergetelijk. Mijn tijd in het Slotervaart 
en OLVG was leerzaam en jullie steun daarin van grate waarde. Margreet Vroom en 
Robert Tepaske dank voor het begrip in de laatste fase van mijn praefschrift en dank 
voor de prettige en uitdagende werkplek op de intensive Care van het AMC. 
Mijn paranimfen Cheryl en Miranda dank voor jullie steun, de motiverende 
gesprekken en input om aan dit traject een waardig, mooi en vooral feestelijk eind 
te breien. 
Mijn lieve lieve familie en vrienden, ik heb jul lie niet altijd de aandacht gegeven 
die jullie verdienen, des te grater is mijn dank dat jullie er altijd voor mij zijn geweest. 
lk put veel kracht uit jullie aanwezigheid in mijn I even. 
Als al lerlaatste de twee mensen die mij het meest dierbaar zijn. Mijn lieve ouders. 
Mijn dank aan jullie is niet in woorden uit te drukken en geen enkele dankbetuiging 
doet jul lie recht. Grantangi dat jullie mij altijd bij elke stap in mijn leven gesteund 
hebben en altijd geloofd hebben in mijn kunnen. Jullie zijn voor mij van onschatbare 
waarde. Grantangi dat ik mag zijn wie ik ben, dank voor jullie liefde. Grantangi 
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